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INTRODUCTION 
  Medicine is an art of fundamental importance to the healthy survival of 
humanity. Siddha, a Medical science is very ancient in origin, as old as the ancient 
civilization. 
  “fy;Njhd;wp kz; Njhd;whf; fhyj;Nj 
   thnshL Kd;Njhd;wpa %j;jf;Fb” 
 
  The word Siddha comes from ‘Siddhi’ which means perfection or healthy 
bliss. It generally refers to the ‘Attama Siddhi’ i.e the eight supernatural powers. Those who 
attained these powers are known as Siddhars. 
 The Universe is composed of five elements viz, Earth, Water, Fire, air Ether 
(Mann, Neer, Neruppu, Kaatru and Aakayam). The human anatomy, physiology, pathology of 
disease, materials for the treatment and the food for sustenance all fall with in the five 
elemental categoriesSiddha medicines revitalize and also rejuvenate the dysfunctional organs. 
According to Siddha system of Medicine diseases are classified into 4448 in number. Kuttam 
(dermatological diseases) is one among them. Kuttam is further classified into 18 types. The 
disease Venpadai is one among them. It is mentioned as “Suvetha Kuttam” in the text ‘Yugi 
Vaithya Chinthamani’.  
 Venpadai otherwise known as Venpulli is a serious cosmetic problem in 
adolescent life, as it affects the self esteem of patients. This is correlated to Vitiligo in modern 
science. 
   Vitiligo is a condition that causes depigmentation of the skin. It occurs when 
melanocytes, (the cells responsible for skin pigmentation,) die or are unable to function. The 
cause of Vitiligo is unknown, but research suggests that it may arise from autoimmune, 
genetic, oxidative stress, neural or viral causes. It is one of the non contagious dermatological 
problems which produce psychosomatic changes in the individual like mental stress, 
depression, social hinderance etc. Nowadays the prevalence of the disease is increasing and 
both male and female children are victims of the disease. Many more medicines described in 
Siddha system for venpulli “SENKONRAI PATTAI KUDINEER” (INTERNAL) and 
“SENKONRAI PATTAI POOCHU(EXTERNAL)”  was selected for the present study which 
are purely herbal medicine, easily available and harmless to infants and children. The 
ingredients of “SENKONRAI PATTAI KUDINEER” and“SENKONRAI PATTAI 
KUDINEER” have the property of controlling  venpulli without any adverse effects.  
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    AIM AND OBJECTIVES 
AIM:   
 The aim of study on venpulli noi is to ensure a name approach in diagnosis 
for the disease by using siddha and modern parameters and find out a safe and effective 
drug.   
OBJECTIVES : 
Ø To explore the most efficacious drug for venpulli. 
Ø To collect the literal evidences regarding the disease venpulli as per Siddha 
System.  
Ø To have a comparative study of the disease in Siddha and Modern aspect. 
(vitiligo) 
Ø To evaluate the disease venpulli clinically by careful examination on aetiology, 
clinical features, investigations, diagnosis, treatment, diet, prognosis, etc.  
Ø To have a clinical study on the venpulli affected children with senkonrai pattai 
kudineer(internal) and senkonrai pattai poochu(external) 
Ø To find out whether any adverse effects caused by  senkonrai pattai 
kudineer(internal) and senkonrai pattai poochu(external) 
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REVIEW OF LITERATURE 
SIDDHA ASPECTS 
VENPULLI 
Synonyms: 
 Venkuttam, Suvetha Kuttam, Venthittu. 
Definition: 
  Venpulli is defined as the discoloration of the skin characterized by the 
presence of the hypopigmented patches of irregular shape in the epidermis of skin and 
sometimes hair also is involved. 
 Siddhar Yugimuni, mentioned this condition as Suvetha Kuttam in his “Yugimuni 
Vaithiya Chinthamani – 800” which is one among the eighteen types of Kuttam.  
 
“¾ÊôÀ¡¸ ¾ÅÇ¿¢Èõ §À¡ø¦Å ÙòÐî 
º÷Å¡í¸Óõ ¦ÅÙò¾¡ü È¡ýÈ¢ ÕõÒõ 
ÁÊôÀ¡¸ ÁÂ¢÷¦ÅÙò¾¡ Äº¡òÂ Á¡Ìõ 
ÅÃ¢×¾Î ×ûÇí¨¸ì Ì¾í ÌöÂó¾¡ý 
¦¿ÊôÀ¡¸ ¦¿ÕôÒôÀð¼Ð §À¡Ä Òñ½¡ö 
¿¢ÈÁ¢Õó¾¡ Äº¡ò¾¢Â¦Áý§È Ô¨Ãì¸ Ä¡Ìõ 
¦ÅÊôÀ¡¸ §ÁÉ¢¦ÂøÄ¡õ ¦ÅÙòÐ Å£í¸¢ø 
¦ÅñÍ§Å¾ Ìð¼¦Áý§È Å¢ÇõÀ Ä¡§Á.” 
                                                   -ä¸¢ ÓÉ¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 800 
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Aetiology:  
 Siddha system attributes the aetiology of the disease to heredity, stress and 
strain, malnutrition and venereal exposure. No specific causes were mentioned for 
Venpulli but general descriptions have been given.  Extrinsic and intrinsic causes 
have been attributed to the manifestation of Venpulli. 
According to “Thirumoolar Karukkadai Vaithiya Nool” 
“Å¢Â¡¾¢Ôñ ãÅ¡Ú Å¢Çí¸¢Â Ìð¼í§¸û 
ÍÂ¡¾¢ì ¸¢Ãó¾¢ ÍÆý §Á¸ò¾¡Ä¡Úõ 
ÀÂ¡¾¢ ÁñÏÇô ÀÄÅñÊÉ¡ ¦ÄðÎõ 
¿¢Â¡¾¢ ÒØ¿¡Ä¡ö ¿¢ýÈ¾¢ì Ìð¼§Á”. 
 Among the eighteen types of Kuttam; six are caused by Kirandhi and 
Megam. Eight types are caused by insects in the soil and the remaining four types are 
caused by Worms. 
2) According to “Yugimuni Vaithiya Chinthamani – 800” the causes for the 18 types 
of Kuttam are mentioned as:  
“Å¢ÇõÀ§Å Á¢Ìó¾¯‰ ½ó¾ý É¡Öõ 
Á¢Ìó¾ º£¾Çò¾¡Ö ÁÆüº¢ Â¡Öõ 
ÅÇõÀ§Å Áó¾ò¾¡ø Å¡ó¾¢ Â¡Öõ 
Á¸ò¾¡É ¦Àñ§½¡Î ÁÕÅ Ä¡Öõ 
¸¢ÇõÀ§Å ¸¢§Äºí¸û Á¢Ì¾ Ä¡Öõ 
¦¸ÊÂ¡É ×Ãì¸í¸Ç ¨¼¾ Ä¡Öõ 
¾ÇõÀ§Å ÁÂ¢Õ¸ü¸û ¾Å¢Î Áñ¸û 
º¡¾ò¾¢ü ÀÕ¸Ä¡ø Á¢ÌìÌí Ì‰¼õ 
Ìð¼ó¾¡ý À¾¢¦ÉðÎ ÅÃ§Å ¦¾ýÉ¢ü 
ÌÕ¿¢ó¨¾ º¢Å¿¢ó¨¾ Á¨È§Â¡÷ ¿¢ó¨¾ 
¾¢ð¼ó¾¡ý §¾Å¨¾¨Âò à„¨½ìÌ §Ã¡¾õ 
¦ºôÀÄ¡ü È¢Õ¼Ä¡ü ÀÃ¾¡ Ãò¨¾ 
«ð¼ó¾¡ É¡¨ºÂ¡Ä ¨¼ì¸ Äò¨¾ 
«À¸Ã¢ò¾ Ä¸¾¢ÀÃ §¾º¢ ¾ý¨É 
Åð¼ó¾¡ý ¨Å¾Ä¡ü ¸üÀ Æ¢ò¾ø 
Åó¾¢Î§Á À¾¢¦ÉðÎì Ìð¼ó ¾¡§É” 
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 Excessive heat and cold exposure, laziness, excessive sleep in day time, 
unbridled sexual indulgence, robbery etc. These habits are supposed to be the factors, 
which lower the immune mechanism of the body (Udal vanmai) and makes the body 
liable for the disease. 
 Excessive intake of food which are hard to digest, imbalanced food and 
vomiting, frequent intake of food mixed with fragments of stone and hair, prolonged 
mental depression, intention to spoil others, raping, greedy, abusing god and noble 
people, neglecting refuges and beggars, cursing the elders are said to the causes for this 
condition. 
3) According to “Agathiyar Vaithyam” 
“ÌÂøÅ¡ö Ì‰¼õ ºÂíÌýÁ ¿£Ã¢Æ¢× ÍÃì¸¢Ã¡½¢ 
             ¿£Ã¨¼ôÒ À¡ñÎ ãÄ Å¡ö× 
¸Âø Å¡Ô ÅÕí¸ñ½¢ø Ìò¾¡ö ¸Êó¾ ¾ºÅ¡ö× 
             ¸¡½Å¡¸ Óý ¦ºö¾ ¯Â¢÷¸Ùõ Å¢¨É¾¡§É”. 
Kuttam may be hereditary, apart from all other etiological factors Kuttam is also 
considered to be followed by Sins committed in the previous birth (Kanma vinai). 
4) According to “Siddha Maruthuvam Sirappu” 
 The aetiology and the characters of Venpadai are clearly explained in the 
text “Siddha Maruthuvam Sirappu” as follows: 
 In the affected area, reduction or total loss of skin pigment melanin on the 
epidermis is observed. As the distinct aetiology is not known, there exist certain beliefs 
and hypothesis about the disease. They are: 1.Constant irritation to the skin owing to 
clothes, rubber, plastics or other chemical substances. 2. Some essential metal or mineral 
deficiency in the food. 
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Classification: 
1) According to “Yugimuni Vaithiya Chinthamani – 800” 
In “Yugimuni Vaithiya Chinthamani – 800”, Kuttam is classified into 18 types. 
Suvetha Kuttam (Venpadai) is one among them. It is mentioned as below: 
“Óò¾¡Ìí Ìð¼ó¾¡ý À¾¢¦Éð ÎìÌõ 
ÓÉ¢Â¡É ä¸¢¿¡ý ¦º¡øÄì §¸Ç¡ö 
      Òò¾¡Ìõ Òñ¼Ã£¸ Ìð¼ò §¾¡Î 
       ¦À¡Õ¸¢ýÈ Å¢ü§À¡¼¸ Ì‰¼ Á¡Ìõ 
      Àò¾¡Ìõ ÀÃÁÌ‰¼õ §¸îÃ Ì‰¼õ 
           ÀÃ¢Å¡É ¸÷½Ìð¼õ º¢ÌÁ Ìð¼õ 
¸¢ò¾¡Ìí ¸¢Õ‰½Ìð¼ «Ð×õÀ÷ Ìð¼õ 
¦¸ÊÂ¡É Áñ¼ÄÌð ¼ÓÁ¡ ¦Áý§É 
Ìð¼Á¡õ ÀÃôÀÃ¢º Ìð¼ ¦Á¡Î  
ÌÊÄÁ¡õ Å¢¸÷îº£¸ Ìð¼ Á¡Ìõ 
Åð¼Á¡õ ¨ÅÂ¡¾¢ Ìð¼ §Á¡Î 
ÁÕÅÄ¡í ¸¢ËÀÌð¼ï º÷Á §¾Åõ 
¾¢ð¼Á¡ §¾ò¾¢Õì Ìð¼ §Á¡Î 
º¢òÐÁ¡ Ìð¼ïº¡ ¸¡ÚÌð¼õ 
Ðð¼Á¡ï Í§Å¾Ìð¼ó ¾ý§É¡ ¦¼¡ì¸î 
ÍÂõÀ¡É À¾¢¦ÉðÎ Ìð¼ Á¡î§º” 
 
1.Pundarega Kuttam   (Padarthamarai Peru Noi) 
2.Virpotaka Kuttam   (Koppula Peru Noi) 
3.Baama Kuttam   (Sirangu Peru Noi) 
4.Gaja Saruma Kuttam  (Yaanaithol Peru Noi, yaega Saruma Kuttam) 
5.Karna Kuttam   (Kaathu Peru Noi) 
6.Sigura Kuttam   (Thol Peru Noi) 
7.Krishna Kuttam   (Karu Peru Noi) 
8.Avudhumbara Kuttam  (Atthikkaai Peru Noi) 
9.Mandala Kuttam   (Valaiya Peru Noi) 
10.Abarisa Kuttam   (Vali Peru Noi) 
11.Visarchika Kuttam  (Sori Peru Noi) 
12.Vibaathika Kuttam  (Sempadai, Senkuttam) 
13.Kideeba Kuttam   (Pandrithol Peru Noi) 
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14.Sarmathala Kuttam  (Tholvedi Peru Noi) 
15.Thethru Kuttam   (Thadippu Peru Noi) 
16.Sithuma Kuttam   (Naa Peru Noi) 
17.Sathaaru Kuttam   (Purai Peru Noi) 
18.Suvetha kuttam   (Venpadai, Venkuttam     
  
2) According to “Pararasa Sekaram” 
Kuttam is classified into 5 types: 
1. Venkuttam 
2. Senkuttam 
3. Karunkuttam 
4. Vishakuttam 
5. Azhukannikuttam 
3) According to “Siddha Maruthuvam Sirappu” 
According to “Siddha Maruthuvam Sirappu”, Venpadai has been classified into 4 
types: 
1. Vatha Venpadai 
2. Pitha Venpadai 
3. Kaba Venpadai 
4. Mega Venpadai 
4) According to “Siddhar Aruvai Maruthuvam” and “Anubava Vaithiya Deva 
Ragasiyam” 
Venpadai has been classified into 3 types on the basis of Mukkutram. They are, 
  1. Vatha Venpadai  
    2. Pitha Venpadai  
    3. Kaba Venpadai.   
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Clinical features: 
1) According to “Yugimuni Vaithiya Chinthamani – 800” 
  Yugimuni shortly attributed the Venpulli under the headline of Suvetha 
Kuttam which is one of the eighteen kuttams and he mentioned the clinical features of 
suvetha kuttam as below: 
“¾ÊôÀ¡¸ ¾ÅÇ¿¢Èõ §À¡ø¦Å ÙòÐî 
º÷Å¡í¸Óõ ¦ÅÙò¾¡ü È¡ýÈ¢ ÕõÒõ 
ÁÊôÀ¡¸ ÁÂ¢÷¦ÅÙò¾¡ Äº¡òÂ Á¡Ìõ 
ÅÃ¢×¾Î ×ûÇí¨¸ì Ì¾í ÌöÂó¾¡ý 
¦¿ÊôÀ¡¸ ¦¿ÕôÒôÀð¼Ð §À¡Ä Òñ½¡ö 
¿¢ÈÁ¢Õó¾¡ Äº¡ò¾¢Â¦Áý§È Ô¨Ãì¸ Ä¡Ìõ 
¦ÅÊôÀ¡¸ §ÁÉ¢¦ÂøÄ¡õ ¦ÅÙòÐ Å£í¸¢ø 
¦ÅñÍ§Å¾ Ìð¼¦Áý§È Å¢ÇõÀ Ä¡§Á.” 
Yugimuni gives a clear definition of Venpulli and he mentioned the conditions 
which will not responded to treatment (Asathiyam) as said below: 
1. Whitish discoloration of the part of the body or entire body. Sometimes hair also 
turns white. 
2. When white patches occur on the palms or muco-cutaneous junctions like lips, 
anus and genitals, it is said to be rarely curable. 
3. If the hair becomes white, prognosis will be very bad. 
4. Fissured body becomes oedematous. 
2) According to “Siddha Maruthuvam Sirappu” 
In the text ‘Siddha Maruthuvam Sirappu’, Venpadai has been classified into 4 
types and the clinical features are also described: 
I. Vatha venpadai 
II. Pitha Venpadai 
III. Kaba venpadai 
IV. Mega Venpadai. 
I. Vatha Venpadai: 
 It is characterized by the presence of depigmented patches, which are dry, 
rough and reddish or somewhat pale-black in color. 
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II. Pitha Venpadai: 
 It is characterized by the presence of depigmented patches red in color like lotus 
flower, spreading with burning sensation and loss of hairs on that area. 
III. Kaba Venpadai:  
               It is characterized by the presence of depigmented patches white in color like the 
flower of Thumbai (Leucas aspera), spreading with itching sensation and mild elevation 
of the lesion. 
IV. Mega Venpadai: 
 It is followed by venereal diseases. It may develop in 4 to 6 months after 
the venereal exposure. This Venpadai develops initially in the nape and the adjoining 
spaces. It then gradually spreads to involve the shoulder joints and back of the trunk. 
  Clinical features: Depigmented patches are small in number, pale in colour 
or light turmeric in colour or dark colour and margins marked by hyperpigmention. These 
lesions are circumscribed with 2 mm to 3 mm diameter or above. This correct picture of 
hypopigmented and hyperpigmented skin seems to be more or less a multi eyed filter 
(sieve like). 
  Females are more prone to this Mega Venpadai and the treatment takes 
longer period. Therefore drugs to be given for the treatment of Mega noi (Venereal 
disease) before treating Venpadai. 
Siddha Pathology: 
 The basic principle of Siddha system is 96 thathuvas of which 
panchapootha theory and mukkutra theory are very important. The pathology in Siddha 
system depends upon the mukkutra theory viz, Vatha, Pitha and Kaba. The normal order 
of Vatha, Pitha Kaba is in proportion of 1:1/2:1/4 respectively.  
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This is stated in the following verses. 
 “toq;fpa thjk; khj;jpiu nahd;whfpy; 
   joq;fpa gpj;je; jd;dp yiuthrp 
  moq;Fq; fge;jhdlq;fpNa fhNyhby; 
   gpwq;fpa rPtHf;Fg; gprf;nfhd;W kpy;iyNa” 
       - Fzthfl ehb 
 
 Imbalance in this results in disease this can be inferred from the following 
Thirukkural.  
  “kpfpDk; FiwapDk; Neha; nra;Ak; E}NyhH 
    tsp Kjyh vz;zpa %d;W”. 
        - jpUts;StH 
Siddhars treated the body as well as mind and have also formulated the ways for 
the prevention of diseases. Siddhars defined medicine as follows, 
  “kWg;gJ cly;Neha; kUe;njd yhFk; 
    kWg;gJ csNeha; kUe;njd rhYk; 
   kWg;gJ ,dpNeha; thuhjpUf;f 
   kWg;gJ rhitA kUe;njdyhNk” 
 
The clinical methods through which the correct diagnosis made out 
by Envagai thervugal and ezhu   udal       kattukal  Basic five principle (Pancha 
boothams) in our system are ingredient for the Thridhosam. That has been formed 
by the union of single or double boothas like as follows. 
Vaatham   =  Vali + Vin 
Piththam   =  Thee 
Kabam   =          Mann + Neer 
 The most important clinical approach of our physicians is to assess the 
status and  function of the above  three thadhus . This has been described as Naadi 
sothanai and Naadi nadai Arithal. 
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The alteration of three thathu in their reaction to extrinsic or intrinsic 
factors results in disharmony. This altered harmony and balance variation of the three 
thathus results in disease. Their natural ratio to each other is discerned by the physician at 
the wrist and each nadi is individually assessed for its strength, speed and regularity. 
Description of Three Humors 
These three humour are divided in to various types and have their 
functions specifically. 
VALI 
According to the physiological function vali is of ten types. They are  
(I)  Uyir Kaal (pranan)       
        This is the first of ten vital airs. According to Yugi muni, pranan starts 
from moolatharam and comes through the nostrils and causes the act of inspiration and 
expiration. The inspiration and expiration are not equal and their ratio is 8:12. The 
process helps in the digestion of ingested food. 
(ii) Kizhnokkumkaal(Abanan)      
Apanan, the downward air, starts from swathittanam and descends towards 
the pelvis and is responsible for excretion of urine and faeces. This is green in color. It 
contracts the anus. It helps to take the essence of the digested food to the different parts of 
the body which requires food. The god attributed is varadarajan. 
(iii) Paravukaal(Vyanan) 
Vyanan arises from the shoulders and go through all the 72,000 nerves and 
thus activate voluntary and involuntary movements of the body and thus make them to 
extend the contract. This appreciates the sense of touch, helps to take the essence of the 
food to the strategic points of the body and guards the body. 
(iv) Melnokkumkaal (Udhanan) 
Udhanan starts from the umbilical region (udarakkini) and takes the 
essence of food and stations it at appropriate places. It helps in digestion and assimilation 
of food. 
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(v) Nadukkal (Samanan) 
Samanan starts from the umbilical cord and spread out up to the 
lowerlimb. This is responsible for the balance of the other four vathas. It equalizes the six 
tastes, water, food etc and helps in assimilation. 
(vi)  Naagan 
Naagan is responsible for higher intellectual functions, hearing, thinking 
etc. It causes closing and opening of the eye lids. 
(vii) Koorman 
Koorman starts from the mind and causes winking of the eyelids, yawning 
and closure of mouth. It gives strength and helps to visualize things and causes lacrimal 
secretion 
(viii ) Kirukaran 
Kirukaran lies in the tongue and causes nasal and salivary secretions. It 
induces hunger. Sneezing and cough are attributed to kirukaran. It is black in color 
(ix)  Devadaththan 
Laziness is attributed to devadaththan. Occular movements and human 
passions are attributed to this vatham. It stays either at the anus or at urinary orifice. 
(x) Dhananjeyan 
Dhananjeyan functions from the nose and it is responsible for the bloating 
of the body after death and also for the foul smell. 
AZHAL 
It is not just heat in our body. Functionally this human bodies warmth/heat 
of life is divided in to five types. They are 
(i) Akkuanal (Analagam) 
It lies between the stomach and the intestine and causes digestion and dries 
up moist ingested substances 
(ii) Vanna eri (Ranjagam) 
This fire lies in the stomach and gives red color to the chyme and produces 
blood. It improves blood. 
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(iii) Attralangi (Sadhagam) 
This fire lies mainly in limbs. It gives energy for activities 
(iv) Nokku Azhal(Alosagam) 
It lies in the eyes and causes the faculty of vision. It helps to visualize 
things. 
(v) Ollolithee (Prasagam) 
It gives color and complexion and brightness to the skin. 
IYYAM: 
It is of five types. They are 
(i) Alli Iyyam  (Avalambagam) 
It lies in the lungs and helps in respiration. It causes firmness of the limbs. 
This is vital among all types of kapham for it controls the other four kapham and 
maintains equilibrium. 
(ii) Neerpi Iyyam (Kilethagam) 
It lies in the stomach. It mixes the consumed food and water and promotes 
the digestive process. 
(iii). Suvaikanna Iyyam (Pothagam) 
It lies in the tongue and helps to realize the taste of the consuming food. 
(iv) Niraivu Iyyam (Tharpagam) 
Sustaining in the head, this gives refrigerant effect to cool the eyes and 
other sense organs. 
(v) Ondri Iyyam (Sadhigam) 
Sustaining in the joints this makes them more freely and easily.Since 
venpadai patients are not having defined description of pathology, the pattern of 
disturbance in Vali, Azhal, Iyyam keeps on varying. The manifestation of these uyir 
thathus keep on changing according to the predominant symptom. But alteration in azhal 
thathu is seen mostly. 
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3.1.8  VO clw; fl;L;fs; (Seven Physical Constituents) 
The human body is made of seven basic, physical constituents. These 
constituents should be in harmony and function normally.Any variation in them will 
lead to their functional deviations.The Natural characters of the seven physical 
constituents. 
(i) SAARAM (Chyle) : This gives mental and physical perseverance. 
ü Increased Saaram : Leads to diseases of increased kapham like indigestion Etc.. 
ü Decreased Saaram : Leads to loss of weight, tiredness, lassitude, dryness of the 
skin and diminished activity of the sense organs. 
(ii) SENNEER : It Imparts color to the body, nourishes the body and is responsible for 
the ability and intellect of an individual. 
ü Increased Senneer : Causes boils in different parts of the body throbbing pain, 
anorexia, mental disorder, splenomegaly,Colicky pain., increased blood pressure, 
reddish eye and Skin, jaundice, haematuria etc. 
ü Decreased Senneer : Leads to anaemia, tiredness, neuritis and lassitude, Pallor of 
body. 
(iii) OON : It gives shape to the body according to the physical activity and and  
           covers the bones. 
ü Increased Oon : Oon in excess causes cervical lymph adenitis, venereal ulcer, 
tumour in face, abdomen, thigh genitalia etc are the signs of increased Oo n 
ü Decreased Oon : Leads to impairment of sense organs, joints jaw, thigh and 
genitalia gets shortened. 
 
(iv) KOZHUPPU : (Adipose tissue): It lubricates the joints and other parts of the body to 
function smoothly 
ü Increased Kozhuppu: Identical to that of increased Oon associated with Dyspnoea 
and loss of acidity.  
ü Decreased Kozhuppu: Leads to pain in the hip region and diseases of the spleen. 
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(v) ENBU : (Bone) :Supports the frame and responsible for the postures and      
movements of the body. 
ü Excess Enbu : Growth in bones and teeth  
ü Decreased Enbu : Loosening of teeth and nails and Splitting and falling of hair. 
 
(vi) MOOLAI : (Bone marrow): It occupies the medulla of the bones and gives strength 
and softness to them. 
ü Increased Moolai : Causes heaviness, swollen eyes, swollen phalanges, Oliguria 
and non healing ulcers 
ü Decreased Moolai : Causes osteoporosis and sunken eyes. 
 
(vii) SUKKILAM / SURONITHAM : (Sperm and Ovum) : It is responsible for 
reproduction. 
ü Excess Sukkilam/Suronitham : Causes lust towards women and cause Urinary 
calculai. 
ü Decreased Sukkilam/Suronitham : Causes failure in reproduction, pain in the 
genitalia. 
 
3.1.9  vz;tif Nju;T (Eight fold Siddha Examinations) 
 Nowadays advanced diagnostic tools have been developed by modern bio-
medical scientists. But Siddhars have given eight diagnostic methodological tools. They 
are called as Envagai thervu. 
(i)  NAA 
 Signs and symptoms in the tongue are considered here. Size, appearance, 
thickness, color(pigmented, magenta) fissured (longitudinal, transverse) coated, 
geographical patches, oral hairy leucoplakia, candida, apthus ulcers, sense of taste, saliva 
secretion 
(ii) NIRAM 
 The color of skin is mainly considered here but also the change in other organs. 
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(iii) MOZHI 
 The change in the normal sound of voice mainly uratha olli (Valithel), thazhntha 
olli (Melithal), physiological and mental status can also be noted during conversation. 
(iv). VIZHI 
 Color, warm, burning sensation, irritation, visual perception. 
(v). PARISAM 
  Observations by touch, temperature, sensory impairment, masses, nodes, 
swelling, texture of the skin, pain, hardness, edematous, and dullness shall be noted. 
(vi).MALAM 
  The stools are examined for quantity, hardening (malakattu) loose motion 
(baethi) color, smell. 
(vii). MOOTHIRAM 
Neer Kuri : Urine is to be obsorbed for the following characters, 
Ø Niram(color) 
Ø Alavu(quantity) 
Ø Edai (specific gravity) 
Ø Manam (smell) 
Ø Nurai (froth) 
Ø Enjal (deposit) 
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3.1.10 NEI KURI 
A unique traditional method for diagnosis with urine is Neikkuri. Urine is 
freshly collected in a clean glass vessel and a drop of Gingili oil is dropped in to it. The 
gingelley oil should be prepared by wooden press. Machine pressed oil is not an effective 
tool. 
Mode of spreading is noted, usually  
Vali noi - Aravu (Snake like spread) 
Azhal noi - AAzhi (Ring like spread) 
Iyyam -Muthu  (Pearl like spread) 
Venpulli starts with disturbed Azhal and eventually involves all the three 
uyir thathus – thus resulting in various patterns of oil spread in the urine surface. An 
unique pattern, is seen mostly like star fish with branches and sieve (plate with pores), 
irregular border, speed of spread is also to be noted. It has been observed that the initial 
star shaped spread reduces as the patients responds to treatment. 
Prognosis of the disease: 
  The prognosis of the disease is also mentioned in Siddha literature: 
1) According to the text “Yugimuni Vaithiya Chinthamani – 800”  
curable types - 10: 
“Ìð¼ó¾¡ý À¾¢¦ÉðÊø º¡ò¾¢ Âó¾¡ý 
  ÜÈì§¸û Å¢ü§À¡¼¸ ÀÃÁü Ìð¼õ 
¸¢ð¼ó¾¡ý §¸îº÷Á Ìð¼ §Á¡Î 
  ¸¢Õ‰½ Ìð¼Á×¾õÀ ÃÌð¼ó ¾¡Ûõ 
¾¢ð¼Á¡ó §¾ò¾¢Õì Ìð¼ §Á¡Î 
  ¦ºÂº¢òÐ Á¡Ìð¼í ¸¢ËÀ Ìð¼õ 
¾ð¼ó¾¡ý Á¢Ìó¾º¡ ¾¡Õ Ìð¼õ 
 ºÁ¸¢Õ‰½ Ìð¼õ º¡ò ¾¢ÂÁ¡ ¦Áý§É” 
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Curable Kuttam  
1. Virpodaga Kuttam 
2. Baama Kuttam 
3. Gaja Sarma Kuttam 
4. Krishna Kuttam 
5. Avuthumbara Kuttam 
6. Thethru Kuttam 
7. Sithuma Kuttam 
8. Kideepa Kuttam  
9. Satharu Kuttam 
10. Sarmathala Kuttam 
 
Incurable Types - 8: 
“¬¦ÁýÈ ÀòÐó¾¡ý º¡òÂ Á¡Ìõ 
  «º¡òÂ ÁÐ¾¡¦ÉðÎ «È¢óÐ À¡Õ 
§À¡¦ÁýÈ â÷Åò¾¢ý ¸ýÁò ¾¡Öõ 
  ÒÅ¢¾Éì ÌõÁ¢Ì¸ýÁï ¦ºö¾ À¡Åõ 
À¡¦ÁýÈ ¦ÀÃ¢§Â¡÷¸û º¡Àò ¾¡Öõ 
  À¡¾¸í¸û ÁÉ¾È¢Âô ÀñÏõ §À÷ìÌõ  
§¸¡¦ÁýÈ Ìð¼Á¡õ §Ã¡¸õ ÅóÐ  
  ÜÎ¦ÁýÚ ä¸¢ÓÉ¢ ÜÈ¢§É§É” 
 
1. Pundareega Kuttam 
2. Karna Kuttam 
3. Sigura Kuttam 
4. Mandala Kuttam 
5. Abarisa Kuttam 
6. Visarchiga Kuttam 
7. Vibaathiga Kuttam 
8. Suvetha Kuttam 
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2) According to the text “Siddha Maruthuvam Sirappu” 
Curable conditions in Venpadai are: 
· Lesions without any change in hair colour. 
· Lesions without coarse texture. 
· Lesions that are not appearing like white burnt scar. 
Incurable conditions in Venpadai are:  
· Lesions with whitened hair. 
· Lesions feeling rough. 
· Lesion appearing like white burnt scar. 
· If the lesion first appears on genitalia, anus palms and lips. 
· Lesions of fast spreading nature. 
 
Management in Siddha: 
  “Á¢¸¢Ûõ Ì¨ÈÂ¢Ûõ §¿¡ö¦ºöÔõ á§Ä¡÷ 
    ÅÇ¢Ó¾Ä¡ ¦Åñ½¢Â ãýÚ”. 
-¾¢ÕìÌÈû. 
 
 According to Siddha System, the main aim of the treatment is to cure 
udarpini (physical illness) and manappini (mental illness). Treatment is not only for 
complete healing but also for the prevention and rejuvenation. 
 In Siddha system, the line of treatment consists of 
1. Neekkam (Treatment) 
2. Niraivu (Rejuvenation of well being) 
3. Kaappu (Prevention) 
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1. Neekkam (Treatment): 
  Siddha system of Medicine is based on Mukkutra Theory and hence the 
treatment is mainly aimed to bring the three thodams to equilibrium state and thereby 
restoring the physiological condition of the seven thathus. 
  
  The three thodams organise, regularise and integrate the bodily structure 
and their functions. They are always kept in a state of balance by thought, word, deed and 
food. Any imbalance will lead to disease. The imbalanced thodams are balanced by 
administrating purgatives or emetics or application of Anjanam (application on eyes) and 
followed by the appropriate systemic therapy by giving Siddha drugs. It mentioned as 
below: 
          "Å¢§ÃºÉò¾¡ø Å¡¾ó ¾¡Øõ". 
   The purgatives should be given before starting the trial to normalize the 
deranged thodams to normal. In this study the purgation is induced by giving Viresana 
Boopathy Tablet - 2 early morning with hot water. 
  Then the next day onwards the trial drugs Panchamuga Chenduram 
(Internally) Poovarasam Pattai Ennai (Externally) were given. 
2. Niraivu (Rejuvenation): 
  Physical, psychological, social and economic rehabilitation and 
reassurance of individuals is known as Niraivu.  
3.  Kaappu (Prevention): 
  As per Siddha science, even at the time of conception some defects may 
occur in the fertilized embryo forming the basic for the manifestation of certain 
constitutional diseases after birth. These are known as Kanma vinaigal. 
Kanma Neekkam (Expiation):  
 To prevent and expiate the misdeeds of the kanmam, planting of trees, 
establishing gardens, laying roads and pathways, digging wells and ponds for public use, 
constructing temples, donating ornaments to poor children must be done. 
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Dietary Advice: 
 In siddha system of medicine the importance of dietary habits also 
emphasiszed for the diseases management and prevention. This line is well understood in 
these verses, 
“¯½§Å ÁÕóÐ ÁÕó§¾ ¯½×”. 
“ÁÕó¦¾É §Åñ¼¡Å¡õ Â¡ì¨¸ìÌ «Õó¾¢ÂÐ 
«üÈÐ §À¡üÈ¢ ¯½¢ý”. 
In diseased condition diet restrictions or paththiyam are strictly followed to 
increase the effectiveness of medicine for curing diseases.  This is given in the following 
verse,  
      “Àò¾¢Âò¾¢É¡§Ä ÀÄý ¯ñ¼¡Ìõ ÁÕóÐ 
Àò¾¢Âí¸û §À¡É¡ø ÀÄý§À¡Ìõ - Àò¾¢Âò¾¢ø 
Àò¾¢Â§Á ¦ÅüÈ¢¾Õõ ÀñÊ¾÷ìÌ ¬¾Ä¢É¡ø 
        Àò¾¢Â§Á ¯ò¾¢¦ÂýÚ À¡÷” 
                               - §¾¨ÃÂ÷ ¦ÅñÀ¡. 
 
Dietary and other restrictions for Venpadai patients:    
    Diet restrictions or paththiyam should be strictly followed in Venpadai 
patients. These are prescribed to normalize the deranged thodam and to increase the 
potency of the drugs. Patients are a 
Patients are strictly advised to follow the dietary and other restrictions: 
· Avoid all non-vegetarian foods except goat’s meat.  
· Avoid food items which are enriched with alcohol.  
· Avoid the Sesban, Brinjal, Kaar arisi, Green plantain, Bitter gourd, Pickles, 
Tamarind,  
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· Vitamin C rich fruits and vegetables like lemon, goose-berry, orange, etc. 
Vitamin C must be avoided in diet, since in the formation of melanin, tyrosine 
plays an important role. But in the metabolic pathway of tyrosine a metabolic 
error happens due to increased presence of vitamin C (Ascorbic acid).  
If this error occurs continuously the tyrosine cannot be absorbed by the body 
and is execrated through urine. 
· To avoid substances allergic to the particular individual. 
· To take Thiridhoda samapporulkal (elam, manjal, seeragam, kaayam, chukku, 
venthayam, poondu, milagu). 
· To take vegetables and green leafy vegetables 
· To take more germinated grams, dates, figs and powder of fenugreek 
regularly.  
· Using of soaps and detergents should be avoided. To take neutral value pH 
soaps for bath purpose. 
· To use Nalunguma a Siddha herbal preparation which contains sandanam, 
vetti ver, vilamacham ver, kichili kizhangu, karbogi, paasipayiru instead of 
soap and other detergents for bath. 
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MODERN ASPECTS 
SKIN 
 
Introduction: 
   The skin is the body's largest organ, covering the entire body. The skin and 
external mucous membranes separate the human organism from the environment and 
accomplish a variety of functions.  
 
 In an adult, the skin surface measures 1.5. to 2 m2 while the thickness of 
the skin varies from fractions of a millimeter to 4 mm. The thickness of the epidermis 
varies from 0.06 - 0.9 mm to 0.5 – 0.6 mm. The thickness of the subcutaneous fat varies 
considerably. Some area is devoid of fat while in others (on the abdomen and gluteal 
regions). It is several centimeters thick. The mass of skin an adult accounts for 
approximately 5% while together with the subcutaneous fat for about 10 to 17.7% of the 
total body mass. 
 
  The color of the skin may change because the amount of the pigment in it 
varies under the effects of external and internal factors. 
  The skin surface is covered with hairs over a great area. The areas devoid 
of hairs are the lips, the palms and soles, the palmar surface of the hand and the plantar 
surface of the toes, the glans penis, the inner surface of the prepuce and the inner surface 
of the labia marjoram and minorum. 
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CROSS SECTION OF SKIN 
Facts about the Skin: 
The skin and external nucleus membranes separate the human organism from the 
environment and accomplish a variety of functions. Normal functioning of the skin and its 
appendages of high significance for the organism activity as a whole and has a positive 
influence on its general condition. 
  The skin not only responds by its adaptive reactions to the different effects of the 
external (exogenic) environmental factors, but is also very sensitive to changes in the 
various body organs and systems and is often the first to signal the development of a 
pathological condition by different changes in its function. Consequently though the skin 
is an independent organ, it at the same time is in a constant dynamic connection with the 
external environment and with all the organs and systems of a human body. The skin 
communicates with the organism by means of the nervous system, circulation and 
endocrine glands. The skin takes an active part in protein, carbohydrate, fat, water, 
mineral and vitamin metabolism. 
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Histology:  
 The skin develops from two germinative zones. The ectoderm which is 
represented by the epidermis (the most superficial skin layer) and the mesoderm (the 
middle embryonal layer) represented by two layers namely the true skin, or dermis (the 
middle layer) and the subcutaneous fat or hypoderm the deepest skin layer. The boundary 
between the epidermis and dermis and dermis forms a wavy line because of the presence 
of skin papillar (special out growth on the surface of the true skin). The spaces between 
which are filled with epithelial processes. 
The skin is divided into 3 divisions: Epidermis, Dermis and Hypodermis 
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Epidermis: 
The epidermis is the most superficial layer of the skin and provides the first 
barrier of protection from the invasion of foreign substances into the body. The principal 
cell of the epidermis is called a keratinocyte.  
The epidermis is subdivided into five layers or strata, 
· The stratum germinativum (stratum basale), 
· The stratum spinosum (malpighian layer), 
· The stratum granulosum, 
· The stratum lucidum and 
· The stratum corneum  
Specialized Epidermal Cells: 
There are three types of specialized cells in the epidermis 
1) The melanocyte produces pigment (melanin)  
2) The Langerhan’s cell is the frontline defense of the immune system in the skin  
3) The Merkel's cell's function is not clearly known 
 
LAYERS OF THE EPIDERMIS                              
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Dermis: 
The dermis assumes the important functions of thermoregulation and supports the 
vascular network to supply the avascular epidermis with nutrients. The dermis contains 
mostly fibroblasts which are responsible for secreting collagen, elastin and ground 
substance that give the support and elasticity of the skin. Also present are immune cells 
that are involved in defense against foreign invaders passing through the epidermis. The 
dermis is typically subdivided into two zones;  
1. Papillary dermis:  
2. Reticular layer: 
 
 
 
 
 
 
 
 
 
Vascular system of skin: 
Vascular system of the skin is formed of several networks of blood vessels. A 
deep arterial plexus of skin forms, which gives rise to branches supplying the holes of the 
sweat glands, the hair follicles and the fat lobules. The epidermis is devoid of blood 
vessels.  
Lymphatic system of the skin:  
 The lymphatic system of the skin forms a superficial and deep network. The 
superficial lymphatic network arises on the papillary layer as blind rounded dilated 
capillaries between which there are numerous anastomosis. The second network of lymph 
vessels is in the lower part of the dermis.  
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Functions of skin: 
Skin performs the following functions: 
· Protection 
· Sensation 
· Heat regulation 
· Control of evaporation 
· Aesthetics and communication 
· Storage and synthesis 
· Excretion 
· Absorption 
· Water resistance 
Sl. 
No 
FUNCTIONS STRUCTURE 
1 Barrier protection:  
 UV rays Melanocytes 
 
Infection & Fluid 
homeostasis 
Keratinocytes 
 Protection from trauma Epidermis & dermis 
2 Thermoregulation 
Blood vessels in superficial & deep dermal 
plexus 
3 Immuno regulation 
Langerhans cells &Inflammatory cells of all 
types 
4 Sense perception  
 Pain, touch, temperature Peripheral nerve trunks 
 Pressure Pacini vater corpuscles 
 Discriminate touch Meissners corpuscles 
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Pigmentation of the Skin: 
The colour of the skin may be brown or even black according to the amount of 
pigment present. Even in white races most parts of the skin contain brown pigment 
granules in the deepest layers of the germinative zone of the epidermis.  
In dark races they are more abundant and extend throughout the whole zone. 
Melanocytes: 
Melanocytes are derived from stem cells in the neural crest that normally migrate 
to the epidermis, where they are scattered along the basal layer. Melanocytes produce 
melanin within cytoplasmic packets called melanosomes. These contain greater amounts 
of melanin in dark - skinned individuals. The melanin is distributed to keratinocytes via 
dendrites when stimulated by exposure to ultraviolet radiation and other factors Melanin  
‘Melanin’ a word is derived from the Greek word Melas, meaning black.Melanin 
is a complex black-brown polymer synthesized from the aminoacid L-DOPA.Melanin is 
endogenous non-haemoglobin derived or brown black pigment(formed). When the 
enzyme tyrosinase catalyses the oxidation of tyrosin to dihydroxy phenylalanine (DOPA) 
in melanocytes. It is widely distributed in the body but peculiarity enough it is limited 
only to those structures which have got an ectodermal origin, for skin, hair, choroid coat 
of retina and substanita nigra of the brain. It is formed from tyrosine by oxidation 
metabolism and polymerization. 
The colour of the skin may be brown or even black according to the amount of 
pigment present. Even in white races most parts of the skin contain brown pigment 
granules in the deepest layers of the germinative zone of the epidermis. In dark races they 
are more abundant and extend throughout the whole zone. 
Distribution: 
It is widely distributed in the body but peculiarity enough it is limited only to 
those structures which have got an ectodermal origin, for skin, hair, choroid coat of retina 
and substanita nigra of the brain. 
30 
 
 It is formed from tyrosine by oxidation metabolism and polymarization.                                       
                                   
 
 
 
 
 
 
 
Melanin Formation: 
  Melanin synthesis is initially catalysed by a copper containing enzyme 
known as tyrosinase. The pathway of melanin synthesis from the oxidation of 
phenylalanine or tyrosine are as follows. 
Tyrosine 
DOPA 
DOPA   quinone. 
     2-Carboxy 2, 3–dihydro–5, 6–dihydroxyindole 
     2–Carboxy –2, 3–dihydro–indole–5, 6–quinone 
        5, 6 Dihydroxyindole 
          Indole-5, 6 Quinone 
    Melanin 
 Melanin formation in both human and amphibian skin is augmented by the 
hormone known as intermedin or melanocyte – stimulating hormone (MSH) secreted by 
the pars intermedia of the pituitary gland. Adrenocartico tropic hormone (ACTH) secreted 
by Anterior Pituitary has melanocyte – stimulating activity similar to MSH although to a 
much lower degree. Melatonin extract from bovine pineal gland, causes concentration of 
melanin near the nuclei of melanocytes in frog and as a result of this the skin becomes 
pallor. Its role in the human is not known. MSH causes the serum copper to rise and this 
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is accompanied by inner case in the melanin formation. Diminished formation of melanin 
is seen in albinism and leucoderma. In melanotic sarcoma, melanin may be found in the 
urine. Melanin absorbs all visible light, ultraviolet (UV), and infrared (IR) radiations. 
Leukoderma (Hypopigmentation) can be subdivided in to two types: 
· Melanocytopenic disorders: Melanocytes are decreased in number or absent.e.g 
Vitiligo. 
· Melanopenic disorders: Absence or reduction in the amount of melanin.  
Melanocytes are present although not functioning   properly. e.g.  Albinism  
VITILIGO 
 The word ‘Vitiligo’ comes from Latin. ‘Viti’ means a mark or blemish, 
‘ligo’ is a common ending meaning to cause. Thus, Vitiligo means ‘to cause a mark or 
blemish’, which is of course what the condition does.  Celeus was the first Roman 
physician of the 2nd century to coin the word Vitiligo, because the disease resembles the 
white patches of a spotted calf (vitelus). The name ‘Vitiligo’ is derived from the latin 
word skin eruption, Victim meaning a blemish (spoil the beauty of) happens to be a 
synonym for it.  
 White skin is the literal meaning of leucoderma, being derived from the 
greek words, leucas and dermis.  Leucas means white and dermis means skin. 
Definition: 
 Vitiligo is a common skin disorder in which there is focal failure of 
pigmentation due to destruction of melanocytes that is thought to be mediated by 
immunological mechanism. It is an acquired idiopathic depigmentary condition and is 
characterized by sharply demarcated, milky white patches with hyperpigmented borders.  
History: 
 Vitiligo is known to the medical word from time immemorial. It is 
mentioned in tarikh-e-tibb-e-Iran. (Persian History of Medicine) vol.I by Dr. Mohmood 
najmabadi, that the disease Vitiligo was known in the period of Aushorryans in 2200 B.C. 
The description of Vitiligo is also found in Athervanaveda which was written in 1400 
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B.C.  The following authors and physicians have mentioned this disease in their works. 
 First in 1914, Danial Turner, dermatologist, described this skin disorder.  
In 1868 addision defined this as a non-infiltrated one. 
Epidemiology: 
 It is most common in India, Egypt, and other tropical countries In India 
most common in Gujarat and Rajasthan. Vitiligo affects 0.5-2% of the world population, 
and the average age of onset is 20 years The incidence of Vitiligo is maximum in India. It 
is about 4% while the incidence is found to be 1.6.4% in Japan, 1% in U.S.A and 0.14% 
in U.S.S.R. Vitiligo may appear at any time from birth to senescence, although the onset 
is most commonly observed in persons aged 10-30 years. The age of onset is unlikely to 
vary between the sexes. Heightened concern about the appearance of the skin may 
contribute to an early awareness of Vitiligo among females .Vitiligo rarely is seen in 
infancy or old age. Nearly all cases of Vitiligo are acquired relatively early in life. 
  It is present in adult life in 25% of patients. About 0.5 to 1 percent of the 
world's population, or as many as 65 million people, have Vitiligo. Vitiligo affects 8.8% 
of population in India. Approximately 30% of Vitiligo cases occur with a familial 
clustering of cases. 
 The overall prevalence of Vitiligo is about 5 per 1,000 individuals. There 
are no significant sex or age differences in prevalence rates. About a 4.5-fold increase in 
prevalence is observed among close biological relatives of affected individuals. There is, 
however, no clearcut correspondence between relative risks and kinship coefficients. 
There are no significant differences in the frequencies of various types of vitiligo between 
probands with and without positive family history. The overall mean and modal ages of 
onset are about 22 years and 15 years, respectively. The mean ages among males (24.8 
years) and females (19.3 years) are significantly different. 
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Patho-physiology: 
 Vitiligo appears to occur when immune cells destroy the cells that produce 
brown pigment (melanocytes). This destruction is thought to be due to an autoimmune 
problem, but the cause is unknown. 
 Vitiligo is a multifactorial polygenic disorder with a complex 
pathogenesis. It is related to both genetic and nongenetic factors. Although several 
theories have been proposed about the pathogenesis of vitiligo, the precise cause remains 
unknown. Generally agreed upon principles are an absence of functional melanocytes in 
Vitiligo skin and a loss of histochemically recognized melanocytes, owing to their 
destruction. However, the destruction is most likely a slow process resulting in a 
progressive decrease of melanocytes.  
 Theories regarding destruction of melanocytes include autoimmune 
mechanisms, cytotoxic mechanisms, intrinsic melanocyte defects, oxidant-antioxidant 
mechanisms, and neural mechanisms. 
1. Autoimmune destruction of melanocytes; 
 The autoimmune theory proposes alteration in humoral and cellular 
immunity in the destruction of melanocytes of Vitiligo. Thyroid disorders, particularly 
Hashimoto thyroiditis and Graves disease; other endocrinopathies, such as Addison 
Disease and Diabetes Mellitus; and Alopecia Areata; Pernicious Anemia; Inflammatory 
Bowel Disease; Psoriasis; and Autoimmune Polyglandular Syndrome are all associated 
with Vitiligo.  
2. Intrinsic defect of melanocytes: 
 Vitiligo melanocytes may have an intrinsic defect leading to melanocyte 
death. These melanocytes demonstrate various abnormalities, including abnormal, rough 
endoplasmic reticulum and incompetent synthesis and processing of melanocytes. In 
addition, homing-receptor dysregulation has also been detected. Early apoptosis of 
melanocytes has also been suggested as a cause of reduced melanocyte survival; however, 
subsequent investigation found that the relative apoptosis susceptibility of Vitiligo 
melanocytes was comparable with that of normal control pigment cells. 
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3. Disturbance in oxidant-antioxidant system in vitiligo: 
 Oxidant stress may also play an essential role in the pathogenesis of 
Vitiligo. Studies suggest that accumulation of free radicals toxic to melanocytes leads to 
their destruction. Because patients with Vitiligo exhibit a characteristic yellow/green or 
bluish fluorescence in clinically affected skin, this led to the discovery that the 
fluorescence is due to accumulation of 2 different oxidized pteridines. The 
overproduction of pteridines led to the discovery of a metabolic defect in 
tetrahydrobiopterin homeostasis in patients with Vitiligo, which results in the 
accumulation of melanocytotoxic hydrogen peroxide. 
4. Neural theory: 
 Case reports describe patients afflicted with a nerve injury who also have 
Vitiligo have hypopigmentation or depigmentation in denervated areas. Additionally, 
segmental Vitiligo frequently occurs in a dermatomal pattern, which suggests that certain 
chemical mediators are released from nerve endings that affect melanin production. 
Further, sweating and vasoconstriction are increased in depigmented patches of Vitiligo, 
implying an increase in adrenergic activity. Finally, increased urinary excretion of 
homovanillic acid and vanilmandelic acid (neurometabolites) has been documented in 
patients with Vitiligo. This may be a secondary or primary phenomenon. 
5. Genetics of Vitiligo: 
 Vitiligo is characterized by incomplete penetrance, multiple susceptibility 
loci, and genetic heterogeneity. The inheritance of Vitiligo may involve genes associated 
with the biosynthesis of melanin, a response to oxidative stress, and regulation of 
autoimmunity. 
 Human leukocyte antigens (HLAs) may be associated, but not in a 
consistent manner. For example, HLA-DR4 is increased in blacks, HLA-B13 is increased 
in Moroccan Jews, and HLA-B35 is increased in Yemenite Jews. An association with 
HLA-B13 is described in the presence of antithyroid antibodies. 
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 The age of onset has a genetic component; in another genomewide 
association study, a quantitative locus for age of onset was found in the major 
histocompatibility complex class II region near a region associated with generalized 
vitiligo susceptibility. 
6. Hereditary Factors 
· Vitiligo has a genetic background.   
· >30% of affected individuals have reported Vitiligo in a parent, sibling or 
child. 
· Vitiligo in identical twins has been reported. 
· Transmission is most likely polygenic with variable expression. 
· The risk of Vitiligo for children of affected individual is unknown but may be 
<10%. 
 Familial incidence has been reported in 7.5 to 21% in India and 33 to 40% 
in western countries. 
7. Allergy History: 
· Occupation 
· Irritant cosmetic things allergy.  Ex. Rubber slipper, gloves etc. 
· Monobenzyl ether of hydroquinone – present in the slipper, gloves or other 
articles of rubber irritate the skin and produce depigmentating disorder. 
· Diet Vinegar, cooking soda and food enriched with alcohol must be avoided. 
These items may promote bleaching of skin pigment. 
 The role of copper in skin pigmentation can be well understood in terms of 
necessity copper for tyrosinase activity. Loss of pigments has been reported in acute zinc 
deficiency. Also reported in vitiligenous skin, zinc and copper contents are decreased. 
· Using soaps and detergents also promote bleaching the skin. 
· Vitiligo is also commonly seen on the flanks of ladies pressure is presumed 
leading to depigmentation. 
· Loss of melanin pigment from the skin often occurs, following wound healing 
scar formation leading to depigmentation.  
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8. Emotional factors: 
 It is every day knowledge and observation that emotional factors affect the 
skin as shown by the blushing of embarrassment, the pallor of fear and depending on the 
subject and his emotional state. Experiments have demonstrated that emotional states can 
affect the following. 
· Which is direct relevance in the aetiology of certain skin disorders.  
· Control of vascularity of the skin. 
· Control of sebaceous gland secretion.  
· Control of sweat. 
· Influencing the degree of oxidation. Influencing the tendency of pruritis. 
 This is due of the causative factor of this disease, venpadai from the 
following basic facts. It is generally considered to be a tropho neurosis. Psychic factors 
are known to be responsible for the precipitation and aggravation of the disease. 
9. Psychology of Vitiligo Patients: 
              Although Vitiligo is usually not harmful medically and causes no physical 
pain, its emotional and psychological effects can be devastating. In fact, in India, those 
with the disease, especially women, are sometimes discriminated against in marriage. 
Developing Vitiligo after marriage can be grounds for divorce. 
 Regardless of a person's race and culture, white patches of Vitiligo can 
affect emotional and psychological well-being and self-esteem. People with Vitiligo can 
experience emotional stress, particularly if the condition develops on visible areas of the 
body (such as the face, hands, arms, and feet) or on the genitals. Adolescents, who are 
often particularly concerned about their appearance, can be devastated by widespread 
Vitiligo. Some people who have Vitiligo feel embarrassed, ashamed, depressed, or 
worried about how others will react. 
 This disease attaches a social stigma. Inferiority complex immediately 
following the start of disease, the patient thinks himself inferior to those with whom he 
was at par or excelled for so long. Naturally, at the beginning the individual tries to hide 
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the patches of lesion and when fails in this effort, the individual often feels shy of friends 
and relatives. When the patient feels his disease is incurable he becomes gradually 
depressed. As the patient tries to feels shy of the surrounding environment, he may 
gradually feel more and more lonely and withdrawn, ultimately plunging in to a state. As 
the disease spreads it may give rise to a state of acute anxiety and insomnia, mixed with 
depression. Idea of reference whenever they sees persons talking at a distance, they thinks  
it is definitely about them and their  disease, which is not generally fact. 
· Depression: when they feel disease is incurable and they becomes gradually 
depressed and it may even lead to suicide. 
· Psychosis: As the patient tries to fight shy of the surrounding environment, they 
may gradually feel more and more lonely and withdrawn, ultimately plunging into 
a psychic state.  Such a patient may have dilution of suspicion / doubt that his or 
her spouse is indulging in adultery, thus bringing in material disharmony.  
· Anxiety: As the disease spreads it may give rise to a state of acute anxiety and 
insomnia, mixed with depression.  
· Aggression (or) Sublimation: He / she may either develop a disbelief in God and 
mankind or become aggressive in his interpersonal behaviour or he / she may give 
way to sublimation and resort to leading a religious life as a possible escape from 
his / her own reality.  
10. Important known causative factors for vitiligo: 
· Nutritional - defects in copper, proteins and vitamins in diet, digestive upsets like 
amoebiasis, helminthics, chronic diarrhoea, dysentery etc., 
· Endocrines - Association with thyrotoxicosis and diabetes. 
· Trophoneurosis and autonomic imbalance – emotional stress and strain. 
· Infections and toxic products, Enteric fever ill health, focal sepsis. 
· Drugs and chemicals - like quinines, guano furacin, amylphenol, chlorthiazide 
broad spectrum antibiotics and chloroquin. 
 Chemicals are known to inhibit melanogenesis, enzymatic actions and 
several chain biochemical reactions. They can also cause interference with nutrition of the 
tissues. Hence tie up of the chemicals and nutrition may provide the answer. Role of food 
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adulterants, industrial chemicals and dyes, contaminating water and foods may be guess 
work at this stage but may prove to be ultimate causes. 
Pathology: 
 In the skin, the pigment is produced by the melanocytes from their 
precursor melanoblasts. The melanoblasts are supposed to be derived from the cells of 
neuro ectodermal origin during the embryonic life. After birth, these cells migrate to their 
definitive position. The melanocytes appear as clear cells within the basal cell layer of the 
epidermis and show dendritic processes after special staining. These processes come in 
contact to similar process of other melanocytes and epithelial cells through which the 
melanin pigments are donated to the basal cells of epidermis. The dermis of normal skin 
also shows macrophages containing melanin pigments known as melanophores, which are 
incapable to produce the melanin pigments. 
 Both the melanocytes and melanoblasts contain the enzyme melanogenase 
or Dopa oxidase, and they are able to convert dihydroxy phyenylalanine into melanin and 
such cells are called DOPA positive. Chemically melanin pigment is a group of chromo 
proteins with coloured prosthetic groups, which is derived from the precursor tyrosine in 
the following way,  
Melanin + Protein = Melano protein 
Tyrosine 
 
Tyrinase 
 
Dihydroxy phenylalanin(DOPA) 
 
Melanogenase 
 
Melanin (Dopa oxidase) 
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Clinical features: 
             Vitiligo manifests as acquired white or hypopigmented macules or patches. 
The onset is slow and the course insidious but enigmatic. It may continue to increase 
slowly or come to a half and then increase again. It is reported that the malady usually 
starts and increasing in the summer months in northern India. 
 The lesions are usually well demarcated, and they are round, oval, or linear 
in shape. The borders may be convex. Lesions enlarge centrifugally over time at an 
unpredictable rate. Lesions range from millimeters to centimeters in size. Initial lesions 
occur most frequently on the hands, forearms, feet, and face, favoring a perioral and 
periocular distribution.  
 Vitiligo lesions may be localized or generalized, with the latter being more 
common than the former. Localized Vitiligo is restricted to one general area with a 
segmental or quasidermatomal distribution. Generalized Vitiligo implies more than one 
general area of involvement. In this situation, the macules are usually found on both sides 
of the trunk, either symmetrically or asymmetrically arrayed. 
 The most common sites of Vitiligo involvement are the face, neck, and 
scalp. Many of the most common sites of occurrence are areas subjected to repeated 
trauma, including the following: 
· Bony prominences 
· Extensor forearm  
· Ventral wrists  
· Dorsal hands  
· Digital phalanges 
 
 Involvement of the mucous membranes is frequently observed in the 
setting of generalized Vitiligo. Vitiligo often occurs around body orifices such as the lips, 
genitals, gingiva, areolas, and nipples. 
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 Body hair (leukotrichia) in vitiliginous macules may be depigmented. 
Vitiligo of the scalp usually appears as a localized patch of white or gray hair, but total 
depigmentation of all scalp hair may occur. Scalp involvement is the most frequent, 
followed by involvement of the eyebrows, pubic hair, and axillary hair, respectively. 
Leukotrichia may indicate a poor prognosis in regard to repigmentation. Spontaneous 
repigmentation of depigmented hair in vitiligo does not occur. 
· Vitiligo is most noticeable in the summer when the normal skin is tanned by the 
sun. The white areas having not protected by pigment are easily made red and sore 
by exposure to sun or artificial ultraviolet light. 
· Early lesions may be pale white and ill defined. At this stage, wood’s lamp helps to 
confirm the diagnosis. Patches enlarge slowly and may affect the whole body. 
Patients skin is susceptible to even minor trauma, it heals with depigmentation. 
· At time lesions develop along the distribution of a peripheral nerve, zosteriform 
vitiligo. It is interesting sometimes to see a bunch of hair burning in that area of 
skin. Occasionally, vitiligo develops around pigmented moles – ‘Halo naevus’. 
· Haemoglobin content of the blood is low and sometimes intestinal parasites and 
infections can be detected. Patients complaint of easy fatiguability.  
· Vitiligo sometimes disappears spontaneously after months or years but more usually 
the conditions spreads slowly and may eventually involve nearly the whole of the 
skin. 
Clinical variants: 
1. Trichrome Vitiligo: 
 Trichrome Vitiligo has an intermediate zone of hypochromia located 
between the achromic center and the peripheral unaffected skin. The natural evolution of 
the hypopigmented areas is progression to full depigmentation. This results in 3 shades of 
color—brown, tan, and white in the same patient, as in the image (1) below. 
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2. Marginal inflammatory Vitiligo:  
 Marginal inflammatory vitiligo results in a red, raised border, which is 
present from the onset of vitiligo (in rare cases) or which may appear several months or 
years after the initial onset. A mild pruritus may be present, as in the image (2) below. 
 
                   
 (1) Trichrome Vitiligo.                  (2) Marginal inflammatory Vitiligo. 
3. Quadrichrome Vitiligo:  
 Quadrichrome Vitiligo is another variant of Vitiligo, which reflects the 
presence of a fourth color (ie, dark brown) at sites of perifollicular repigmentation. A case 
of pentachrome Vitiligo with 5 shades of color has also been described. 
4. Blue Vitiligo:  
 Blue vitiligo results in blue coloration of vitiligo macules. This type has 
been observed in a patient with postinflammatory hyperpigmentation who then developed 
Vitiligo.  
5. Koebner phenomenon: 
 Koebner phenomenon is defined as the development of Vitiligo in sites of 
specific trauma, such as a cut, burn, or abrasion. Minimum injury is required for Koebner 
phenomenon to occur. 
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Classification: 
 The classification system is important because of the special significance 
assigned by some authorities to each type of Vitiligo. The most widely used classification 
of Vitiligo is localized, generalized, and universal types and is based on the distribution, 
as follows:  
1. Localized Vitiligo: 
1. Focal: This type is characterized by one or more macules in one area, most 
commonly in the distribution of the trigeminal nerve.  
2. Segmental: This type manifests as one or more macules in a dermatomal or 
quasidermatomal pattern. It occurs most commonly in children. More than half the 
patients with segmental Vitiligo have patches of white hair or poliosis. This type of 
Vitiligo is not associated with thyroid or other autoimmune disorders.  
3. Mucosal: Mucous membranes alone are affected. 
2. Generalized Vitiligo: 
1. Acrofacial: Depigmentation occurs on the distal fingers and periorificial areas. 
2. Vulgaris: This is characterized by scattered patches that are widely distributed. 
3. Mixed: Acrofacial and Vulgaris Vitiligo occur in combination, or Segmental 
and Acrofacial Vitiligo and/or Vulgaris involvement are noted in combination.  
3. Universal vitiligo: 
 This is complete or nearly complete depigmentation. It is often associated 
with multiple endocrinopathy syndromes. 
Classification of Vitiligo by Progression, Prognosis, and Treatment: 
 When progression, prognosis, and treatment are considered, Vitiligo can 
be classified into 2 major clinical types: Segmental and Non Segmental, as demonstrated 
in the images below.  
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1. Segmental: 
 This usually has an onset early in life and rapidly spreads in the affected 
area. The course of segmental Vitiligo can arrest, and depigmented patches can persist 
unchanged for the life of the patient.  
2. Non-segmental: 
This type includes all types of vitiligo, except segmental vitiligo. 
 
 
 
 
 
 
 
 
Segmental Vitiligo                   Non Segmental Vitiligo 
 
 A single-center study of 213 patients aged 17 years or younger with 
Segmental or Non Segmental Vitiligo found that Non Segmental Vitiligo was more 
strongly linked than Segmental Vitiligo to markers of autoimmunity or inflammation such 
as halo naevi and thyroid antibodies; patients with Non Segmental Vitiligo were also 
more likely to have a family history of Vitiligo or autoimmunity. 
  
.          
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Clinical criteria for classification on Vitiligo:  
Stage of Clinical Features: 
Active (V1)    
i)   New lesions developing 
           ii)   Lesions increasing in size 
           iii)  Border ill defined 
Quiescent (V2)  
i)  No new lesions developing 
      ii)  Lesion stationary in size 
     iii)  Border hyperpigmented and well-defined. 
Improving (V3) 
          i)  Lesions decreasing in size 
       ii)  No new lesions developing 
      iii) Border defined and signs of spontaneous repigmentation (follicular and 
                 peripheral). 
 
Differential diagnosis: 
· Usually in macular leprosy, seborrhoeides, pityriasis versicolour and nevoid 
condition, its assistance is called for. 
· In Piebaldism the lesions are present at birth, are usually confined to the head and 
trunk and rarely show a hyper-pigmented border. 
· Careful examination of the texture of the unpigmented skin should exclude lichen 
sclerosus and scleroderma. 
· Hypomelanosis of the affected skin is commonly seen in pityriasis alba, producing 
slightly scaly areas with rather ill defined edges of children’s faces. 
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· Hypopigmented, slightly scaly macules are seen in pityriasis versicolor. Examination 
of the skin in long wave UVR helps distinguish whether there is total depigmenation 
(as in Vitiligo) or not. It may also detect areas of depigmentation not easily seen in 
ordinary daylight, as well as detecting a lemon-yellow fluorescence seen in some 
cases of Pityriasis versicolor. Absence of scaling, crusting and itching help to 
eliminate seborrhoeids and pityriasis versicolor. These areas often fluorescence a 
golden yellow when examined under a Wood’s lamp.  
 
· The hypomelanotic macules in leprosy are anaesthetic. 
· Addison Disease 
· Chemical leukoderma  
· Idiopathic Guttate Hypomelanosis 
· Malignant Melanoma 
· Mycosis fungoides mimicking Vitiligo 
· Post inflammatory depigmentation 
· Prior treatment with corticosteroids 
· Scleroderma 
· Tinea Versicolor 
· Treponematosis 
· Tuberous Sclerosis 
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Differential Diagnosis of the important Depigmentary Disorders: 
Distinguish 
Features Albinism 
Naevus 
Depigmentosus Vitiligo Leprosy Pityriasis 
Age 
Congenital 
present at 
Birth 
Congenital 
present at birth 
Acquired 
and age Any age Any age 
Distribution Complete (or) partial Unilateral Any area Any area 
Trunk, Neck 
and face 
Course Stationary 
Does not 
increasing in 
size or 
changing shape 
Progressive Progressive 
Progressive 
worse in 
monsoon and 
summer 
Hyper 
pigmentary 
Border 
Nil Nil Present Inflammation Nil 
Heredo 
familial Hereditary Not hereditary May be Nil Nil 
Other 
Features 
Hair and 
eye may 
be 
affected 
Nil Nil 
Anesthesia 
thickned 
nerves, nasal, 
bleeding slit 
smear and 
biopsy 
Furfuraceous 
like dandrufy 
scaling in 
head macules 
and large 
patches 
fungus on 
micro scopic 
examination 
 
Diagnosis: 
· The distribution, the age of onset and the hyper pigmented border will suggest the 
diagnosis. 
· Vitiligo areas are milky white while other lacks this milky white colouration. 
· It is usually apparent. In doubtful and early case, Wood’s lamp is of great help in 
diagnosis. 
· Post-inflammatory leucoderma, which is frequent in the darker races, shows an 
irregular mottling of hyper pigmented and hypopigmented blotches. 
· Stationary patches are well-defined and have hyperpigmented borders. 
· Sensations are normal, so is texture unless the patches have been irritated with 
treatment. 
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Prognosis: 
 It has improved considerably in recent years because of better 
understanding of etiological factors and advances made in therapy. Analyses of cases 
which have failed to respond have usually shown the following features: 
1) Poor nutritional state or digestion, use of broad – spectrum antibiotics over long 
periods. Emotional stress and nervous debility. 
2) Presence of Vitiligo on resistant sites like the hands and the feet, front of wrists, 
the elbows, the waist, the eyelids and lips. 
            3) Depigmented hair in vitiliginous areas.  
Management: 
 At the very outlet, the patient and the relatives should be assured about its 
non-infectious and non-hereditary nature; further that it has no relationship to leprosy 
what so ever. This gives immense moral strength to the patient. 
 Patient should be instructed to avoid physical trauma, as for as possible, 
broad-spectrum antibiotics should not be prescribed for intercurrent illness to Vitiligo 
patients. 
a. Control of etiological factor:  
 The patients nutritional state is improved as far as possible, this Vitamin-B 
of particular importance when the vitiligo is active progressively increasing.  
Multivitamins by mouth and injection of crude liver extract with vitamin B complex are 
beneficial. 
b. Treatment:  
 The main goal of treating Vitiligo is to improve appearance. The choice of 
therapy depends on the number of white patches; their location, sizes, and how 
widespread they are; and what you prefer in terms of treatment. Each patient responds 
differently to therapy, and a particular treatment may not work for everyone. Current 
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treatment options for Vitiligo include medication, surgery, and adjunctive therapies (used 
along with surgical or medical treatments). 
Medical therapies: 
 A number of medical therapies, most of which are applied topically, can 
reduce the appearance of Vitiligo. These are some of the most commonly used: 
1. Topical steroid therapy: 
 Steroid creams may be helpful in repigmenting (returning the color to) 
white patches, particularly if they are applied in the initial stages of the disease.  
2. Psoralen photochemotherapy:  
 Also known as psoralen and ultraviolet a therapy (PUVA) therapy, this is 
probably the most effective treatment for vitiligo available in the United States. The goal 
of PUVA therapy is to repigment the white patches. Psoralen is a drug that contains 
chemicals that react with ultraviolet light to cause darkening of the skin. The treatment 
involves taking psoralen by orally or applying as topically. 
3. Depigmentation: 
 This treatment involves fading the rest of the skin on the body to match the 
areas that are already white. For people who have Vitiligo on more than 50 percent of 
their bodies, depigmentation may be the best treatment option.  
Surgical therapies: 
 The surgical therapies must be considered only after proper medical 
therapy is provided. They are 
1. Autologous skin grafts: 
2. Skin grafts using blisters: 
3. Micropigmentation (tattooing): 
4. Autologous melanocyte transplants: 
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Diet and other advices:  
· If anyone above is the reason for allergy it must be avoided. 
· The patient’s nutritional state has to be increased as high as possible. This is very 
particular when vitiligo is active and progressively increasing. 
· Highly nutritious food like spinach, pomegranate, cheese, butter, milk, almond, 
germinating grams and foods rich in tyrosinase to be added. 
· Vitamin-C (Ascorbic acid) must be avoided in diet. 
· During bathing – the powder of Bengal gram and green gram or any other herbal 
products can be used. 
· Vinegar, cooking soda, food enriched with alcohol must be avoided. These items 
may promote bleaching of skin pigment. 
· Using soaps and detergents also promote bleaching of skin. 
· Copper and zinc content vegetable such as cooked green gram or bengal gram at 
least one time a day. 
· The role of copper in skin pigmenation can be well understood in terms of 
necessity of copper for tyrosinase activity. Loss of pigments has been reported in 
acute zinc deficiency. Also reported in vitiligenous skin, zinc and copper contents 
are decreased. 
· Vitiligo is also commonly seen on the flanks of ladies. Pressure is presumed to 
lead to depigmentation. 
o Avoid irritant cosmetic   
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DRUG REVIEW 
FbePh; 
 
NtWngah;: 
 
 kUe;JePh;> cz;zPh; 
 
 
,ay;: 
 
 cyh;e;j ruf;FfisahtJ> <uKs;s ruf;FfisahtJ Rj;jk; nra;J 
tWf;f Ntz;baitfis tWj;Jk;> ,bf;f Ntz;baitfis ,bj;Jk; 
mjDld; 16gq;F ePh; Nrh;j;J  ½gq;F> ¼ gq;F> 1/8 gq;F, 1/16 gq;F fha;r;rp 
mUe;jp vLg;gJ FbePh; my;yJ fpahok;. 
(kUe;J nra; ,aYk; fiyAk;) 
 
nrq;nfhd;iw 
(CASSIA MARGIUATA) 
 
gad;gLk; cWg;G - G+ gl;il 
Rit   - ifg;G 
jd;ik  - ntg;gk; 
gphpT   - fhh;g;G 
 
 
nrq;nfhd;iw FbePh; 
nra;Kiw: 
  17 - 35fp gl;ilia ed;whf ,bj;J 16 gq;F ePh; tpl;L 1/8 
gq;if FWf;fp vLj;Jf;nfhs;s Ntz;Lk;.  
 
msT: 15 kp.yp - 30 kp.yp. 
 
jPUk;Neha;: ntz;Gs;sp 
ehs;:  40 ehl;fs; 
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        Fzghlk; %ypif Pg 403 
                                      (CASSIA MARGIUATA) 
 
 
gw;W: 
 
 ,iy> gl;il> Nth; ,tw;wpd; rhw;iwahtJ> miuj;J rpy 
ruf;Ffis Rlitj;jhtJ my;yJ Rlitf;fhkyhtJ NehAs;s ,lj;jpy; 
jpz;ikahf mg;Gjy;. 
(kUe;J nra; ,aYk; fiyAk;) 
 
nrq;nfhd;iw G+r;R 
 
 17-35fp gl;il J}is xd;whf ePh;tpl;L miuj;J ntz;Gs;sp cs;s 
,lj;jpy; G+r Ntz;Lk;. 
 
jPUk; Neha;: ntz;Gs;sp 
Fzghlk; %ypif Pg 403 
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4. Materials and Methods 
Patients suffering from venpulli selected for this study. Patients were well 
examined and diagnoses were confirmed with the consultation and direction to the 
Kuzhandhai Maruthuvam department. Then and their opinion of the modern pediatric 
professor was obtained. The protocol for the study was prepared and presented in the IEC 
and got approved.  
The methodology was strictly followed as per the protocol the details of 
the protocol are attached in the annexure. 
Clinical Study 
4.1 Study Design  
This was the open clinical observational study. There was no group for 
blinding. Eligible children with Venpulli i.e. who were fulfill the inclusion criteria for this 
study were enrolled and strictly follow the ASU clinical research guidelines. 
SENKONRAI PATTAI KUDINEER and SENKONRAI PATTAI POOCHU were 
distributed to the parents/ guardians of the children and label showed extensive details 
about the usage of the drug and also demonstrated practically.  
4.2 Population and Sample Size 
· Children affected with Venpulli were enrolled for the study.  
· Dosages of the experimental drug have been calculated as per the Siddha text.  
· Duration of the treatment period was 40 days and according to the patient 
requirement have prolonged. 
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4.3 PREPARATION OF TRIAL DRUGS: 
Medicine Name:  
Internal: Senkonrai kudineer 
Dosage**: 15-30ml b.i.d 
Refernce:.GunapaadamMooligaivaguppu  Part-I (Page No: 403). 
5-7yr……15ml b.i.d(marunthuseiiyalumkalium ) (ScihitchaRatnaDeepam) 
· 8-12yr……30ml b.i.d (marunthuseiiyalumkalium ) (ScihitchaRatnaDeepam ) 
· ** Dose calculation for pediatric group is based on Height and Weight chart, 
ICMR, 1990; and the formula mentioned in the Essential of medical 
pharmacology by K.D. Tripathi 
 
External:  Senkonrai poochu  
Duration: 40 days 
Standard Operating Procedurefor Senkonrai Kudineer (Int) & Senkonrai Poochu (Ext)  
Source of Trial Medicine:  
            The required drugs for preparation of  senkonraikudineer(Int) 
&senkonraipoochu(ext) will be purchased from a well reputed country shop and medicine 
is purified & prepared in Gunapadam lab of National institute of Siddha. 
Method of Preparation:   
Senkonrai Kudineer (Internal) 
Ingredints    : Senkonraipattai                                         
Botanical Name  :  Cassia margiuata                                                    
Weight       :   8gm-16gm 
A drug is purified and grind into a coarse of powder. Add to this  1:16pangu   of water, 
boiiedupto 1/8of it original 
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Senkonrai Poochu: (External) 
Ingredints    : Senkonraipattai                                               
Botanical Name   : cassia margiuata 
A drug is purified and grind then mixed with water and made as paste  
Dosage: 
Internal 
5 to 7 years –  15 ml 
8 to 12 years –  30 ml 
External 
As need 
Indication: Venpulli 
4.4 SUBJECT SELECTION CRITERIA: 
4.4.1 Inclusion criteria: 
      a. Age 5 to 12 years  
      b. Patients, who are having classical symptoms like  
1. Hypo-pigmented patches of the skin without any structural changes.  
2. Patients willing to participate in trial and signing consent by fulfilling the 
conditions of Proforma.  
3. Willing to give blood sample for lab investigations when required. 
4. Willing for photograph before and after treatment. 
4.4.2 Exclusion Criteria: 
  a. A patients is not eligible for admission to the trail if any following is 
applicable 
1. Juvenile Diabetes mellitus 
2. Albinism 
3. Burns 
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b. Patient not willing to give biological sample whenever required. 
c. Patient not willing to give consent for the study  
4.4.3 Withdrawl Criteria: 
a. Exacerbation of symptoms  
b. Occurrence of any adverse effect such as diarrhea, abdominal discomfort. 
c. Patient turned to unwilling during the course of trial drug. 
4.5 Methods Would Be Followed During The Course Of Study: 
· The suspected patients were examined clinically and screened using screening 
form. 
· If they met all inclusion criteria and not meeting any exclusion criteria, the 
patients were enrolled for this study.  
· The patients who are to be enrolled were informed about the study, trial drug, 
possible outcomes and the objectives of the study in the language and terms 
understand able to the patients and informants. 
· After ascertaining the informant’s willingness, informed consent was obtained in 
writing from them in the consent form. 
· These patients were given unique registration number. 
· . Screening form was filled up. History Proforma 
· Clinical assessment and Laboratory investigations were used for recording the 
patient’s history, clinical examination of signs and symptoms and lab 
investigations respectively. 
· Patients were advised to take the trial drug and appropriate dietary advice given 
according to the patient’s and informants perfect understanding. 
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4.6 Assessment And Tests 
4.6.1 Clinical Assessment 
1. Site 
2. Re-pigmentation  
3. Number of lesions 
4. New  Colour change  
5. Size of the lesions 
6. Borders 
7. Erythema 
8. Re-pigmentation of  Hair 
4.6.2 Siddha Method Of Assessment 
a) Poriyal arithal  
b) Pulanal arithal 
c) Vinathal  
d) Uyirthathukkal  
e) Udal thathukkal 
f) Envagai thervugal 
4.6.3 Laboratory Investigation 
Blood Test : 
· Total WBC Count 
· DC-  Polymorphs 
· Lymphocytes  
· Eosinophils  
· Monocytes  
· Basophils  
· Total RBC count  
· ESR 
  Urine Test:  
· Albumin 
· Deposit 
· Puscells 
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 4.7  Data Management: 
· After enrolling the patient in the study, separate files for each patient were opened 
and all forms were filed in the file. Whenever study patient visits OPD during the 
study period, the respective patient file were taken and necessary recordings were 
made at the assessment form or other suitable form. 
·  The screening forms were filled separately. 
· The Data recordings were monitored for completion and adverse event by HOD 
and data logical recording and completeness were monitored by statistician (Sr. 
Research Officer (Statistics). All forms were further scrutinized in presence of 
Investigators by Sr.ResearchOfficer (Statistics) for logical errors and 
incompleteness of data before entering onto computer to avoid any bias. No 
modification in the results is permitted for unbiased report. 
· Any missed data found in during the study, were collected from the patient 
· All collected data were entered using MS access software onto computer. 
· Investigators were  trained to enter the patient data and cross checked by SRO. 
 
4.8 Results Observational Grading: 
a. Good Improvement   : Turning to normal skin 
b. Moderate Improvement  : Reduction in size of all the lesions                        
c. Mild Improvement   :Reduction in size of selected lesions 
d. No Improvement  : Static- remains the same - (no further 
lesions formed). 
4.9 Ae / Sae Management  
 If the patient is found to have any Adverse Effect / Serious Adverse Effect 
that were immediately informed to IEC and also treateds for the untoward reactions. 
  
58 
 
4.10 Data Collection Forms: 
a. Screening and selection Proforma 
b. Consent form 
c. History Proforma on enrollment 
d. Clinical Assessment for during and after treatment assessment 
e. Laboratory investigation on enrollment 
f. Withdrawal  form 
g. Diet Advice  
 
4.11 Statistical Analysis: 
Changes in subjective parameters will be analyzed using paired X2 – test and 
changes in objective parameters will be analyzed using paired t – test. 
 
4.12 Ethical Issues: 
a. To prevent any infection, while collecting blood sample from the patient, 
only disposable syringe, disposable gloves, with proper sterilization of lab 
equipments were used. 
b. The formulation mentioned in the, GUNAPADM MOOLIGAI 
VAGUPPU, will only be used for the study. 
c. No other external or internal medicines are used. There is no infringement 
on the right of patient.  
d. The data collected from the patient were kept confidentially. The patient 
was informed about the disease and treatment. 
e. After the consent of the patient (through patient consent form), he/she 
were enrolled in the study.  
f. Treatment were provided free of cost.  
g. In conditions of treatment failure, adverse reactions, patients were given 
alternative treatment at the National Institute of Siddha with full care 
through the end. 
h. The Director, H.O.D, SRO and Ethical members can monitor the patient  
 profile at any time regarding the research. 
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5. RESULTS AND OBSERVATIONS 
 
Clinical Study: 
Under the clinical study the following parameters have been adopted to meet the 
efficacious and philosophical values.  
1. Age reference  
2. Sex reference  
3. Religion reference 
4. Socio Economic status of the reference 
5. Etiology reference 
6. Family history reference 
7. Paruva kaalam 
8. Diet reference  
9. Site of lesion 
10. Derangement in the types of Vatham 
11. Derangement in the types of Pitham 
12. Derangement in the types of Kabam 
13. Ezhu Udar Kattugal reference 
14. Ennvagai Thervugal reference 
15. Distribution of nadi among the patient with Venpadai 
16. Results after treatment reference 
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Age Reference 
Table -5: 
 
 
 
 
 
Chart No – 1  
 
Table above bar diagram showed age reference of our clinical study 
 
 The above table and chart showed the Age references in our study 
population. In our study 67% of the patients from the age group of 8 – 12 years and 33% 
of the children from the 5-7 years. 
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Age (in Years) 
No. of Cases 
(Out of 40) 
Percentage % 
5-7 Years 13 33 
8-12 Years 27 67 
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2. Sex Reference 
Table -6: 
 
Chart No – 2 
     
Table above bar diagram showed Sex reference of our clinical study. 
 
 The above table and chart showed the Sex references in our study 
population. In our study 29   (58%) were Female Children and 21 (42%) were Male 
children. 
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Sex No. of Cases (Out of 40) Percentage% 
Male Children 21 42 
Female Children 19 58 
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3. Religion Reference: 
Table -7 
Religion 
No. of Cases 
(out of 40) 
Percentage 
% 
Hindu 33 82 
Christian 4 10 
Muslim 3 8 
 
Chart No – 3 
 
Table above bar diagram showed Religion reference of our clinical study. 
 The above table and chart showed the Religion references in our study 
population. In our study most of the children belong  to Hindu (82%), then Christians (10 
%.) and Muslims (8%) children. 
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4.socio economic status: 
Table -8 
Socio – Economic Status 
No. of Cases 
(out of 40) 
Percentage 
% 
Lower Income Group 10 25 
Middle Income Group 20 50 
High Income Group 10 25 
 
Chart No – 4 
 
Table above bar diagram showed Economic status reference of our clinical study 
 The above table and chart showed the Economic status references in our 
study population. In our study about 50% of the parents were middle income group and 
25% lower, and 25% high income children. 
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Etiology Reference:  
Table -9 
 
Chart No – 5 : 
 
Table above bar diagram showed Etiology reference of our clinical study 
 The above table and chart showed the Etiology references in our study 
population. In our study about 78% of the cases were of unknown aetiology and 15% 
Anemia cases, 7% hereditary childrens. 
  
Hereditary
7%
Anemia
15%
Unknown
78%
Etiology 
Etiology 
 
No. of Cases( out of 40) 
Percentage 
% 
Hereditary 3 7 
Anemia 6 15 
Unknown 31 78 
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6. Family History Reference: 
Table -10: 
Family History No. of Cases out of 40 
Percentage 
% 
Present 2 5 
Absent 38 95 
 
Chart No – 6 
         
Table above bar diagram showed Family history reference of our clinical study 
 The above table and chart showed the Family history references in our 
study population. In our study About 95% cases were having no family history absent and 
in 5% of cases family history was present  
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7. Paruvakaalam: 
Table -11: 
Paruvakaalam No. of Cases out of 40 
Percentage 
% 
Kaarkaalam 28 70 
Koothirkaalam 12 30 
Munpani 0 0 
Pinpani 0 0 
Elavenil 0 0 
Mudhuvenil 0 0 
 
Chart No – 7 
 
Table Above Bar Diagram Showed Paruvakaalam Reference Of Our Clinical Study. 
  
The above table and chart showed the Sex references in our study population. In 
our study Paruvakkalam, highest incidence (70%) was noted in Karkaalam and 
Koothirkalam 30% children were noted. 
0
10
20
30
40
50
60
70
70%
30%
0% 0% 0% 0%
Paruvakaalam 
Kaarkaalam
Koothirkaalam
Munpani
Pinpani
Elavenil
Mudhuvenil
67 
 
8.Diet Reference: 
Table -12: 
Food Habit No. of Cases( out of 40) 
Percentage 
% 
Vegetarian 8 20 
Mixed 32 80 
 
Chart No – 8 
 
Table above bar diagram showed Foot habit reference of our clinical study 
  
 The above table and chart showed the Foot habit references in our study 
population. In our study 32 cases were taken mixed diet and 8 cases have Vegetarian  
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9. Site of Lesion: 
Table -13: 
Site of Lesion No. of Cases (out of 40) 
Percentage 
% 
Scalp 3 8 
Face 3 8 
Lips 2 5 
Chest 4 8 
Upper Limb 4 10 
Lower Limb 3 8 
Genital 2 5 
Multiple 19 48 
 
Chart No – 9  
 
 Table above bar diagram showed percentage of Site of lesion Reference of 
our clinical study. 
 Exposed areas of the body were multiply involved in 19 (40%) patients, 
Scalp 3 (8%), Lips 2(5%), Chest 4 (8%), Lower limb in 3 (8%) patients, upper limb 4 
(10%), and face in 3 (8%) cases. Genitals were the least affected area, in 2 (5%) patients 
only. Symmetrical lesions were found in 22% patients. 20% had a single lesion 23% had 
less than 10 lesions and 8% patients had more than 10 lesions. 
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10.  Derangement in the types of Vatham: 
Table -14: 
Classification No. of Cases (out of 40) Percentage % 
Piranan 20 40 
Abanan 12 30 
Viyanan 40 100 
Uthanan 12 30 
Samanan 40 100 
Nagan 4 10 
Koorman 2 5 
Kirukaram 0 0 
Devathathan 0 0 
Dananjeyan 0 0 
 
Chart No – 10  
 
Table above bar diagram showed Vatham reference of our clinical study 
  
 The above table and chart showed the Vatham references in our study 
population. In our study of Viyanan and Samanan was deranged in 100% Piranan was 
40%, Uthanan was deranged in 30% Nagan 10% Abanan  9% Koorman 5%in children. 
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11. Derangement in Types of Pitham 
Table -15: 
Types Of Pitham No. of Cases  (out of 40) Percentage% 
Analapitham 0 0 
Ranjagam 10 25 
Saathagam 0 0 
Prasagam 40 100 
Alosagam 3 8 
 
Chart No – 11  
 
Table above bar diagram showed Pitham reference of our clinical study 
 
 The above table and chart showed the Pitham references in our study 
population. In our study Prasagam was affected in 100%, Ranjagam was affected in 25% 
Alosagam was affected in 8% children. 
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12. Derangement Types of Kabam: 
Table -16: 
Types of Kabam No. of Cases (out of 40) 
Percentage 
% 
Avalambagam 20 50 
Kilethagam 3 8 
Pothagam 0 0 
Tharpagam 0 0 
Santhigam 0 0 
 
Chart No – 12  
 
Table above bar diagram showed kabham reference of our clinical study 
  
                       The above table and chart showed the Kabam references in our 
study population. In our study Avalambagam was deranged in 50%, Kilathagam 
was affected in 8%. of children. 
  
0
5
10
15
20
25
30
35
40
45
50
50%
80%
0% 0% 0%
Kabham
72 
 
13. Ezhu Udal Kattugal reference: 
Table -17: 
Udal Kattugal No. of Cases(outof40) 
Percentage 
% 
Saaram 40 100 
Senneer 40 100 
Oon 40 100 
Kozhuppu 0 0 
Enbu 0 0 
Moolai 0 0 
Sukkilam/Suronitham 0 0 
Chart No – 13 
 
Table above bar diagram showed udal kattugal reference of our clinical study 
 The above table and chart showed the udal kattugal references in our study 
population.  Saaram was affected in 100% of cases Senneer was affected in 100% of 
cases Oon was affected in 100% children. 
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14. Distribution of nadi among the patient with Venpulli: 
Table -18; 
Nadi No. of Cases (out of 40) 
Percentage 
% 
Vali  Azhal 8 20 
Vali  Iyyam 3 8 
Azhal  Vali 15 37 
Azhal   Iyyam 0 0 
Iyya  Vali 11 27 
Iyya  Azhal 3 8 
 
Chart No – 14: 
 
Table above bar diagram showed Naadi distribution reference of our clinical study 
    The above table and chart showed the naadi distribution references in our 
study population Azhal vali was observed in 37% Iyya vali was observed in 27 % Vali 
azhal was observed in 20. Vali Iyyam 8% Iyya azhal 8%. 
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15.RESULTS 
Table -19: 
Results No. of Cases percentage 
Good improvement  0 0 
Moderate improvement  6 15 
Mild improvement  30 75 
No improvement 4 10 
 
Chart No – 15  
 
Table above bar diagram showed result reference of our clinical study 
 
 The above table and chart showed the result references in our study 
population. In our study mild improvement was observed in 75 % Moderate improvement 
was observed in 15 %   No improvement was observed in 10 % children.  
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BEFORE AFTER Before 
Urine test 
After 
Urine test S. 
NO 
0p/ip 
NO 
Age/ 
Sex 
TC DC   ESR HB RB
C 
TC DC Esr Hb Rb
c 
P L E ½ ½ P L E ½ ½ Alb Dep Alb Dep 
01 C19194 8/M 7700 51 44 5 3 6 10.8 3.0 7,900 55 43 2 2 4 11.2 3.6 Nil 2-4pus,2-4epi Nil 1-2pus1-2 epi                   
02 B83764 12/M 7600 62 36 2 2 4 11.6 3.8 7,800 54 44 2 2 4 11.5 3.6 Nil 1-2pus, 1-
2epi 
Nil 1-2 pus1-2epi 
03 C4583 12/M 6800 60 36 4 2 4 10 3.2 6.,900 60 38 2 2 4 12.1 3.5 Nil 1-2pus0-1epi Nil 1-2pus,1-2epi 
04 C10158 10/F 5800 45 48 7 5 10 6.3 2.5 6,500 45 49 6 4 8 10.0 3.0 Nil 1-2pus1-2epi Nil 1-2 pus1-2epi 
05 C13752 5/M 8200 58 35 7 4 8 10.2 2.7 8500 55 35 5 2 4 10.5 3.2 Nil 2-4 pus 2-
4epi 
Nil 1-2pus1-2epi 
06 C15778 10/F 7000 50 46 4 6 12 10.4 3.2 7,200 58 38 4 2 4 10.6 3.2 Nil 1-2 pus 2-
4epi 
Nil 1-2 pus0-1epi 
07 B34028 5/M 8400 40 50 10 2 4 7.5 4.0 9,000 48 44 8 2 4 9.7 3.6 Nil 1-2pus1-3epi Nil 1-2 pus1-2epi 
08 C11546 8/F 6000 32 50 18 2 4 8.7 4.0 6,800 45 48 7 2 4 10 4.0 Nil 1-2pus1-2epi Nil 1-2pus1-2epi 
09 C16175 5/F 7000 63 33 4 2 4 10.8 3.4 7500 56 42 2 2 4 11.2 3.8 Nil 2-4pus2-4epi Nil 1-2 pus1-2epi 
LABORATORY INVESTIGATION 
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10 C6610 9/F 8000 53 42 5 4 8 10.3 3.8 7.500 53 42 5 4 8 11.0 4.0 Nil 1-2pus2-6epi Nil 1-2 pus1-2epi 
11 B97717 12/F 9200 44 51 5 2 4 10.8 3.5 8,000 52 40 8 2 4 11.5 4.0 Nil 0-1pus1-2epi Nil 1-2pus0-1epi 
12 B16100 11/M 6900 60 34 6 2 4 9.7 4.0 7,200 53 43 4 2 4 11.0 4.0 Nil 0-1pus1-2epi Nil 0-1 pus1-2epi 
13 B69005 11/M 6800 39 41 20 2 4 9.2 3.4 7,200 52 42 5 1 2 10.0 3.5 Nil 0-1pus1-2epi Nil 1-2 pus0-1epi 
14 C15093 12/M 8000 63 33 4 4 8 9.5 3.0 8200 55 43 2 2 4 11.0 3.5 Nil 1-2pus1-2epi Nil 0-1pus1-2epi 
15 B90193 12/F 9600 36 49 15 8 16 10.8 4.0 9,800 55 44 1 4 8 11.2 4.0 Nil 1-2pus1-2epi Nil 1-2pus 0-1epi 
16 B82913 5/M 6000 32 50 18 6 12 10.8 3.5 6,200 53 43 4 2 4 11.0 3.8 Nil 2-4pus2-4epi Nil 1-2 pus1-2epi 
17 B82913 12/M 7000 52 46 2 4 8 10.2 3.2 7,200 54 44 2 10 4 11.5 3.5 Nil 4-6pus2-4epi Nil 1-2 pus 1-2epi 
18 B48261 8/F 5400 55 45 5 11 22 11.0 3.0 6,500 55 43 2 2 4 11.5 3.0 Nil 2-4pus1-2epi Nil 1-2 pus 0-1epi 
19 C11003 12/F 4600 53 39 8 2 4 9.9 3.5 6,200 53 43 4 2 4 11.0 3.5 Nil 1-2pus1-2epi Nil 1-2 pus1-2epi 
20 C14601 8/F 6500 31 60 9 2 4 10.9 4.0 7000 58 38 4 2 4 11 3.8 Nil 1-2pus2-4epi Nil 1-2pus1-2epi 
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 BEFORE AFTER Before 
Urine test 
After 
Urine test S. 
NO 
0p/ip 
NO 
Age/ 
Sex 
TC DC   ESR HB RB
C 
TC DC Esr Hb Rb
c 
P L E ½ ½ P L E ½ ½ Alb Dep Alb Dep 
21 B76935 10/F 8400 53 33 14 4 8 11.2 3.0 8,700 55 43 2 2 4 11.0 3.6 Nil 0-2pus,0-1epi Nil 1-2pus0-1 epi                   
22 B77653 8/M 6000 58 40 2 4 8 7.5 3.8 6,700 52 42 6 2 4 11.2 3.6 Nil 2-4pus, 3-
6epi 
Nil 2-4 pus2-4epi 
23 B81269 12/F 6300 57 42 1 2 4 11.7 3.2 6.,900 60 38 2 2 4 12.1 3.5 Nil 4-8pus4-8epi Nil 1-2pus,1-2epi 
24 B43177 8/F 6600 54 43 3 3 8 8.2 2.5 6,900 56 42 2 2 4 10.9 3.0 Nil 2-3pus1-2epi Nil 1-2 pus1-2epi 
25 A8658 9/M 6800 53 41 6 6 14 9.5 2.7 7,000 55 43 2 2 8 10.5 3.2 Nil 1-2 pus 0-
1epi 
Nil 1-2pus0-1epi 
26 B85951 8/F 8400 42 48 10 8 16 9.2 3.2 7,200 42 51 7 4 8 10.0 3.2 Nil 3-4 pus 1-
3epi 
Nil 1-2 pus0-1epi 
27 C10061 6/F 8400 52 46 2 4 8 9.5 4.0 8,700 58 41 1 2 4 10.4 3.6 Nil 2-3pus1-2epi Nil 2-4 pus0-1epi 
28 B95663 11/F 6600 60 36 4 3 6 10.6 4.0 6,800 55 45 5 2 4 11.5 4.0 Nil 1-3pus2-4epi Nil 1-2pus1-3epi 
29 B48795 8/M 7000 60 36 4 4 8 9.1 3.4 7200 56 42 2 2 4 10.4 3.8 Nil 4-6pus2-4epi Nil 1-2 pus1-2epi 
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30 C15202 5/M 6300 40 53 7 2 4 10.3 3.8 7.000 53 42 5 2 4 10.5 4.0 Nil 1-2pus2-4epi Nil 1-2 pus1-2epi 
31 B43277 10/F 9500 79 20 1 4 8 10.4 3.5 12,200 52 40 8 2 4 12.5 4.0 Nil 2-4pus4-5epi Nil 1-2pus1-2epi 
32 A8758 11/F 5900 53 43 4 4 8 10.8 4.0 7,200 53 43 4 2 4 12.0 4.0 Nil 0-1pus1-2epi Nil 0-1 pus1-2epi 
33 C4096 6/F 7300 39 55 6 4 8 10.4 3.4 7,200 52 46 2 2 4 11.0 3.5 Nil 1-2pus1-2epi Nil 1-2 pus0-1epi 
34 848 10/F 6800 45 52 3 15 30 9.7 3.0 7,000 55 43 2 4 10 10.5 3.5 Nil 1-2pus1-2epi Nil 1-2pus1-2epi 
35 851 5/F 6500 45 52 3 15 30 9.7 4.0 7,200 55 44 1 5 8 10.2 4.0 Nil 1-2pus1-2epi Nil 1-2pus 0-1epi 
36 857 6/F 8400 42 48 10 4 8 10.0 3.5 8,000 56 42 2 2 4 11.0 3.8 Nil 2-4pus2-4epi Nil 1-2 pus1-2epi 
37 849 12/F 8000 45 52 3 14 28 10.2 3.2 7,200 54 44 2 7 10 11.2 3.5 Nil 4-6pus2-4epi Nil 1-3 pus 0-1epi 
38 883 12/F 8000 44 52 4 2 4 10.6 3.0 8,500 55 43 2 2 4 11.5 3.0 Nil 2-4pus1-2epi Nil 1-2 pus 0-1epi 
39 846 6/M 7600 42 44 11 6 12 8.6 3.5 7,400 53 43 4 2 6 11.0 3.5 Nil 1-2pus2-4epi Nil 0-1 pus1-2epi 
40 861 7/F 6500 40 58 2 4 8 10.2 4.0 6,300 58 38 4 2 4 10.6 3.8 Nil 1-2pus2-4epi Nil 1-2pus1-2epi 
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Op no : B 43277 
Name : Bhuvaneswari  
A/S : 10 / F 
  Before treatment  
   
  After treatment 
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6. DISCUSSION 
The Siddha systems of medicine concentrate on the changes that occur in Vatham, 
Pitham and Kapam. These are responsible for the maintaining the normal equilibrium of the 
body. Venpulli is characterized by depigmentation in various parts of the body especially in 
orifices, eyes, nostrils, mouth, nipples, umbilicus, and genitalia etc. While the depigmented areas 
are painless they can be a source of embarrassment and emotional stress. Nowadays the 
Prevalence of the disease is increasing in children are victims of the disease. It may be 
resemblance with Vitiligo, according to the definition given in medical scientific literature.  
Management of Venpulli is often difficult and frustrating, both for the patient as well as the 
physician.  The treatment commonly practicing dermatologist are topical corticosteroids; topical 
immunomodulators; phototherapy, including PUVA, topical PUVA, UVB and monochromatic 
excimer laser or light, as well as micro phototherapy; surgical options including autologous mini-
punch grafting; blister roof grafting, and epidermal cell transplantation. It require prolonged use 
of these agent which results in significant therapy limiting side effects likely atrophy , hyper 
trichinosis, perilerional, hypo pigmentation etc. For this study the Internal and external Siddha 
poly herbal formulations from authenticated Sathric texts were chosen, Selected experimental 
drugs are namely SENKONRAI PATTAI KUDINEER(INTERNAL) SENKONRAI PATTAI 
POOCHU(EXTERNAL) for the management of Venpulli.   
In this study children with Venpulli were enrolled  in our Department of 
Kuzhandhai Maruthuvam and examined the children with Siddha diagnostic method.  Before and 
after the course of treatment patients were subjected to laboratory investigations and photographs 
were taken. 
The primary challenge for achieving feasibility was the recruitment of 40 
participants aged 5 to 12 years old in the specified time period.  It could be argued that the 
parents are some of the most psychologically fragile, where looks and social pressures have the 
most impact, thus the children targeted for this study as the need to treat their Venpulli was 
perceived to be the greatest. Although many people inquired about the study, we had difficulty 
recruiting the young participants specified in the inclusion criteria. Our findings are consistent 
with a previous report showing effectiveness in treating vitiligo with Siddha formulations.  
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 Among the 40 children of both the gender 21 (42 %) were male children and 
29(58%) were female children. Therefore we didn’t come to the conclusion, the Venpulli have 
affected for particular gender. In Dietary Habits, 32 (80%) children were non -vegetarians and 8 
(20 %) were vegetarian. This result showed simply we have enrolled non-vegetarian children in 
higher percentage. In Vatham, Samanan and Viyanan were affected for all those children. These 
both vayu are physiologically placing on the all over the body including skin.         
 The most likely confounding factor, however, is sun exposure, as it can stimulate 
the proliferation of melanocytes and affect the production of vitamin D, both of which can 
impact vitiligo. This study by starting in august, but some participants were recruited late in the 
summer, and completed the 40days study in November, thus experiencing substantial decreasing 
intensity of sun exposure over the last few months of their treatment. Most studies of Venpadai 
treatment set a 75% repigmentation rate as cosmetically acceptable, and are able to achieve it in 
12.5 to 75% of patients after one year of treatment. But we have treated for only 40 days. Hence, 
we couldn’t get cosmetically accepted repigmentation. There were no adverse events attributed 
to the study  SENKONRAI PATTAI KUDINEER and SENKONRAI PATTAI POOCHU  did not 
adversely affect serum WBC, LFT and RFT parameters. Given the inclusion of children 
participants in this study, much care was taken to monitor adverse events experienced due to the 
taking of SENKONRAI PATTAI KUDINEER and SENKONRAI PATTAI POOCHU. Our results 
suggest that the experimental formulations did not have a negative impact on these serum 
parameters. The impact of on serum parameters was not the primary outcome of our study, thus 
the study was not powered to evaluate the significance of these results.  
As one of the common herbal medicine in the Siddha system of medicine, and 
accounting for more prescriptions in India, the use of  senkonrai for Venpulli is appealing due to 
the ease of use of taking an oral compared with frequent and lengthy ultraviolet phototherapy 
sessions, and the relatively inexpensive cost of the herbal supplement when compared to 
phototherapy.Further, the relatively good safety profile of  senkonrai pattai chooranm makes it 
appealing for self administration by Venpulli sufferers. However, it is recommended that any 
attempt to use senkonrai pattai kudineer and poochu and in the management of Venpulli should 
be carefully monitored by a Siddha practitioner given that there are still many questions about 
the correct dose, its true effectiveness, interactions with other conditions or therapies, and 
possible adverse reactions. 
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 There are several limitations to our study  senkonrai pattai kudineer and poochu 
at warrant discussion. The purpose of this study was to assess the feasibility of studying for the 
management of the Venpulli in a larger, blinded randomized controlled trial and as such this 
study was difficult designed to allow us to draw clear conclusions about its efficacy. The sample 
size was small, thus our findings are preliminary and definite conclusions about the efficacy and 
safety of the experimental formulations difficult be made. Because the study was open labeled, 
not controlled, and not randomized, it is quite likely that some of the demonstrated benefit. 
However, this is unlikely that all of the results we report can be accounted for by spontaneous 
repigmentation. 
 Our primary outcome measure has a degree of subjectivity associated with it. We 
attempted to strengthen the objectivity of the outcomes by us, and by verifying assessments 
using digital photographs. However, we assessed to approximate the area of Venpulli lesions and 
their intensity. Being the participants were children, the parents may also have impacted the 
results, as sufferers can respond more quickly to treatment. It is possible that the relatively 
smaller lesion sizes and durations in our Participants could have resulted in over-estimating the 
effectiveness of treatment.  Despite these limitations, estimation of effectiveness that can be used 
to estimate a sample size for a larger study. And the results are compelling enough to proceed 
with a larger trial. This study focused on determining the feasibility of a future large randomized 
controlled trial of  senkonrai pattai kudineer and poochu  for the treatment of Venpulli. Given 
that our small study found statistically significant improvement on some secondary outcome 
measures, a larger methodologically rigorous double blind placebo- controlled randomized 
clinical trial is recommended. 
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                 7.  SUMMARY & CONCLUSION 
 
A number of drugs are available in the market, which have achieved improved 
efficacy and safety after incorporating the active agents in carrier systems. Therefore, putting 
new life into erstwhile discarded drug molecules by transforming them into novel formulations 
can serve as viable and cost effective alternative to the expensive and time consuming search of 
newer alternative drugs and therapies in Siddha systems of medicine. Efficacy of ‘SENKONRAI 
PATTAI KUDINNER  with topical application of  SENKONRAI PATTAI POOCHU was 
showed to various categories. Clinical outcomes showed moderate improvement in 15%, mild 
improvement in 75% and No improvement in 10% of children. There was no adverse events 
noticed in throughout the study and the experimental formulations were cost effective. The 
results are better in children. Body and lower limb lesions respond much quickly as compared to 
lesions in other parts of the body while lesions on joints have relatively lower response. During 
our study, senkonrai pattai kudineer and poochu didn’t show any adverse events as like Psoralen 
compounds, Placental extracts, Steroids (topical or systemic). 
  
In recent time, Sasthric traditional Siddha formulations, and a better knowledge of 
the physicochemical and phytochemical properties of herbs and formulations have led to the 
development of evaluated Siddha drug delivery systems that have the potential to re-invent the 
internal and topical treatments of Venpulli (vitiligo). There is hope and enthusiasm from this 
study that further research enhanced collaboration with dermatology researchers will bring this 
hitherto untapped potential to fruition.  
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BACKGROUND : 
 Vitiligo is an acquired idiopathic dermatological disorder characterized by well 
circumscribed milky-white macular devoid of identifiable melanocytes  
 It affects approximately 1% of world population in which 3-4% of Indian 
population had vitiligo. It affects both sexes equally in all races however it is more noticeable in 
people with dark skin 
 There is no cure for vitiligo but there are a number of treatments that improve the 
condition.  
 In modern medicine the conventional treatment is corticosteroid. Tropical steroid 
are often first line therapy especially in child. It require prolonged use of these agent which 
results in significant therapy limiting side effects likely atrophy, hyper trichinosis, perilerional, 
hypo pigmentation etc   
 Due to the significant side effects  caused by the usage of the Modern medicine, 
there is a need to explore a remedy for this disease. 
 Dermatological problems pose a great threat and challenge in the developing 
scientific world. It affects the humans’ personality physically and psychologically. 
  Siddha system of medicine is an ancient system of medicine. It is developed by 
Siddhars – the man who attained perfection in life. Siddha system not only deals with external 
body but also with the inner man or the soul. 
 In siddha system of medicine all the skin diseases have been brought under 18 
types of  Kuttam described in Yugi Vaidhya Chinthamani written by Siddhar Yugi. 
 The symptoms of the disease “VENPULLI” which is one of the skin disease 
coincides to the maximum with the symptoms of the disease “VITILIGO” 
 So, I proposed to carry out the study on Venpulli (Vitiligo) a chronic skin ailment 
with the trial drug SENKONRAI KUDINEER, and SENKONRAI POOCHU – indicated for 
Venpulli.  
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AIM & OBJECTIVES :  
PRIMARY OBJECTIVE:   
          To establish the clinical evaluation of the Venpulli by careful examination on 
aetiology, symptomatology, treatment, prognosis and correlate with Vitiligo  
SECONDARY OBJECTIVE:   
· To evaluate the clinical efficacy of senkonrai kudineer (Int) &  
senkonraipoochu(Ext)  in the treatment of  VENPULLI (VITILIGO). 
 
Materials and Methods: 
STUDY DESIGN & CONDUCT OF STUDY: 
STUDY TYPE: 
 An open clinical trial 
STUDY PLACE:  
OPD & IPD. Of Ayothidass pandithar hospital 
National institute of siddha ,  
Tambaram sanatorium, Chennai-47. 
  STUDY PERIOD:  
12 months 
POPULATION AND SAMPLE: 
· Population consists of pediatric patients attending the OPD of Ayothidoss Pandithar 
Hospital, National Institute of Siddha, Chennai-47. 
· The sample consists of patients 5-12 years age group fulfilling all the inclusion criteria 
and exclusion criteria. 
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SAMPLE SIZE: 40 patients 
SUBJECT SELECTION: 
                As and when patients reporting with symptoms of venpulli and fulfilling inclusion 
criteria will be subjected to screening test & documented using screening proforma. 
INCLUSION CRITERIA 
2. Hypo-pigmented patches without any structural changes. 
3. Age:  between 5 - 12 years of both sex 
4. Patients willing to participate in trial and  sign in consent form 
5. Willing to give blood sample for lab investigations when required. 
6. Willing for photograph before and after treatment. 
EXCLUSION CRITERIA: 
1. Juvenile Diabetes mellitus 
2. Albinism 
3. Burns 
4. HIV 
WITHDRAWAL CRITERIA 
· Intolerance to the drug & development of adverse reactions   during drug trial. 
· Poor patient compliance & defaulters. 
· Patient turned unwilling to continue in the course of clinical trial. 
· Occurrence of any serious illness 
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TREATMENT: 
MEDICINE NAME:  
 Internal: Senkonrai kudineer 15-30ml b.i.d .Gunapaadam  Mooligai vaguppu  
Part-I (Page No: 403). 
External:  Senkonrai poochu  Gunapaadam Mooligai vaguppu  Part-I (Page No:403)  
DOSAGE:**  
· 5-7yr……15ml b.i.d(marunthu sei iyalum kalium ) (Scihitcha Ratna Deepam) 
· 8-12yr……30ml b.i.d (marunthu sei iyalum kalium ) (Scihitcha Ratna Deepam ) 
 
** Dose calculation for pediatric group is based on Height and Weight chart, ICMR, 1990; 
and the formula mentioned in the Essential of medical pharmacology by K.D. Tripathi    
  
DURATION: 40 days 
 STANDARD OPERATING PROCEDURE FOR SENKONRAI KUDINEER ( 
Int ) &  SENKONRAI POOCHU(Ext)  
SOURCE OF TRIAL MEDICINE:  
            The required drugs for preparation of  senkonrai kudineer (Int) & senkonrai 
poochu (ext) will be purchased from a well reputed country shop and medicine is purified & 
prepared in Gunapadam lab of National institute of Siddha. 
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METHOD OF PREPARATION:           
SENKONRAI KUDINEER (INTERNAL) 
INGREDINTS                 BOTANICAL NAME                 WEIGHT               
Senkonraipattai                     Cassia margiuata                      8gm-16gm 
          A drug is purified and grind into a coarse of powder. Add to this  1:16 pangu   of 
water, boiied upto 1/8of it original                                                                      
SENKONRAI POOCHU:(EXTERNAL) 
      INGREDINTS                 BOTANICAL NAME      
       Senkonraipattai          cassia margiuata 
 
A drug is purified and grind then mixed with water and made as paste  
INDICATION: VENPULLI 
ASSESMENTS & TEST 
A. Clinical assessment  
B. Routine investigations 
C. siddha method assessment 
A.CLINICAL ASSESMENT: 
       Site 
Repigmentation  
Number of lesions 
New  Colour change  
Size of the lesions 
Borders 
Erythema 
Repigmentation of  Hair 
Itching 
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B.ROUTINE INVESTIGATION 
BLOOD 
· Hb 
· Total WBC Count 
· DC-  Polymorphs 
· Lymphocytes  
· Eosinophils  
· Monocytes  
· Basophils  
· Total RBC count  
· ESR 
URINE 
         Albumin 
         Deposits 
 C. SIDDHA METHOD OF ASSESSMENT 
 Nilam, Kalam, Uyirthathukkal, Udal Thathukkal, Envagai Thervugal, Neerkuri, 
Neikuri. . 
STUDY ENROLLMENT  
 Patients reporting at the OPD with the clinical symptoms of Hypo pigmentation, 
itching, burning sensation etc will be examined clinically for enrolling in the study based on the 
inclusion and exclusion criteria.  
 The patients who are to be enrolled would be informed about the study, trial drug, 
possible outcomes and the objectives of the study in the language and terms understandable to 
them. 
 After ascertaining the patient’s willingness, informed consent would be obtained 
in writing from them in the consent form (Form IV). All these patients will be given unique 
serial number. 
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 Complete clinical history, complaints and duration, laboratory findings-- all 
would be recorded in the prescribed Proforma. Screening Form- I will be filled up. Patients 
would be advised to take the trial drug and appropriate dietary advice would be given according 
to the patients perfect understanding. The patients are requested to bring back the unconsumed 
trial drug.  
CONDUCT OF THE STUDY: 
 The trial drug SENKONRAI KUDINEER (Internal) is given for 40 days. The trial 
drug SENKONRAI POOCHU is given continuously for 40 days for external application. For 
OP patients, they should visit the hospital once in 15 days.  At each clinical visit clinical 
assessment is done and prognosis is noted. For IP patients the drug is given for 40 days. For IP 
patients’ clinical assessment is done daily. Laboratory investigations are done 0day&40 th day of 
the trial. For IP patients, who is not in a situation to stay in the hospital for a long time is advised 
to attend the OPD for further follow- up. After the end of the treatment, the patient is advised to 
visit the OPD for another 2 months for follow-up. If any patient who fails to collect the trial drug 
on the prescribed day but wants to continue in the trial from the next day or two, he/ she will be 
allowed, but defaulters of one week and more will not be allowed to continue and be withdrawn 
from the study with a fresh case being included. 
DATA MANAGEMENT 
· After enrolling the patient in the study, a separate file for each patient will be opened 
and all forms will be filed in the file. Study No. and Patient No. will be entered on the 
top of file for easy identification. Whenever study patient visits OPD during the study 
period, the respective patient file will be taken and necessary recordings will be made 
at the assessment form or other suitable form. 
· The screening forms will be filed separately. 
· The Data recordings in all forms will be monitored and scrutinized by HOD, Dept of 
kuzhanthai maruthuvam . 
Data analysis will be done with the help of senior research officer (statistics) of NI 
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OUTCOME 
 Primary – Results and observation during the study inclusive of clinical improvement 
etc. 
Secondary – Efficacy of the trail  drug and its side effects if any. 
 ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT: If the trial 
patient develops any adverse reaction, he/she would be immediately withdrawn from the trial and 
proper management will be given in OPD of National Institute of Siddha 
ETHICAL ISSUES 
1. To prevent any infection, while collecting blood sample from the patient, only disposable 
syringes, disposable gloves, with proper sterilization of lab equipments will   be used.                         
2. No other external or internal medicines will be used. There will be no infringement on the 
rights of patient.    
3. The data collected from the patient will be kept confidentially. The patient will be informed 
about the diagnosis, treatment and follow-up.  
4. After the consent of the patient (through consent form) they will be enrolled in the 
study.(Proper consent will be obtained from patient informer/guardian to document photos) 
5. Informed consent will be obtained from the patient explaining in the understandable language 
to the patient. 
6. Treatment would be provided free of cost.  
 In conditions of treatment failure, adverse reactions, patients will be given 
alternative treatment at the National Institute of Siddha with full care throughout the end.  
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1. FORM USED: 
FORM I - SCREENING & SELECTION PROFORMA 
FORM  II - CONSENT FORM 
 
FORM  III - HISTORY PROFORMA  
 
FORM IV - CLINICAL ASSESSMENT FORM 
 
FORM  V -LABORATORY INVESTIGATION FORM 
 
FORM VI -PATIENT’S INFORMATION SHEET  
 
FORM VII     - WITHDRAWAL FORM 
 
FORM VIII - ADVERSE REACTION FORM 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI –600047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
             A  study on “VENPULLI” (VITILIGO)  and the drug of choice is 
SENKONRAI KUDINEER (Internal) & SENKONRAI POOCHU(External).             
I  SCREENING FORM  
 
1. OP / IP No.: ________     2. Patient ID no:         3.Name: ________________ 
 
4. Age:   _______ 5.Gender: Male/Female  6.Patient informant: _________ 
 
7. Date: ___________ 8.Reliablity _________   9.Contact No.___________________ 
 
INCLUSION CRITERIA 
· Age :5-12Yrs                                                                                          
· Sex : Both male and female child                                                                    
· Patients having of symptoms of Hypo-pigmented patches without any structural changes  
      Yes / No                                                                    
· Patients  are willing to give blood and urine for laboratory investigations      
Yes / No                                                                   
· Patient  parents or guardian willing to sign the informed consent stating that he/she will 
conscientiously stick to the treatment during 40days but can opt out of the trial of 
his/her Own conscious discretion    Yes / No   
                                                
· Willing to take photograph before and after treatment.               
        Yes / No 
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EXCLUSION CRITERIA 
1. Juvenile Diabetes mellitus 
2. Albinism 
3. Leprosy 
4. Burns 
5. HIV 
6. Patients with any other serious illness.       
Patients Admitted to trial: __________________     
 
(Signature of principle investigator)     (Signature of Lecturer) 
 
 
 
 
  
96 
 
NATIONAL INSTITTUTE OF SIDDHA  
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
 
A open clinical study to evaluate the safety and efficacy of senkonrai pattai kudineer 
(internal) senkonrai pattai poochu” (external) in treating ‘’venpulli” (vitiligo) 
II CONSENT FORM 
Certificate by Investigator 
 I certify that I have disclosed all details about the study in the terms readily 
understood by the parent. 
Date:           Signature: 
          Name: 
Consent of the informant: 
 I have been informed to my satisfaction, by the attending physician, the purpose 
of the clinical trial, and the nature of the drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my son/daughter body functions.  
 I am aware of my right to opt out of the trial to my son/daughter at any time 
during the course of the trial without having to give the reasons for doing so. 
 I, exercising my free power of choice, hereby give my consent to include my 
son/daughter as a subject in the clinical trial of Nilapanai kilangu Chooranam Kandangkathiri 
Pazha Thailam” (External) in the treatment of  Venpullii” (Vitiligo) 
Name :         Signature: 
Date:          Relationship: 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI –600047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
             A  study on “VENPULLI” (VITILIGO)  and the drug of choice is 
SENKONRAI KUDINEER (Internal) & SENKONRAI POOCHU(External).             
III PROFORMA 
Demographic data 
 Patient Id : OP/IP No. Visit Date : (__/__/____) 
Name :  
Age    :  
Gender                Male             Female Date Of Birth : (__/__/____) 
Father/ Mother /Guardian Name :   
Fathers Occupation :   
Fathers Monthly  Income :   
Religion : 
 
 
 
Socioeconomic Status : 
 
 
Patient Informant :   
 
Postal Address 
 
 
 Contact No : 
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Complaints and Duration: 
Present illness: 
History of Past Illness: 
History /Symptoms/Signs  Yes  No  If, Yes Details 
Any Similar Complains  
Bronchial Asthma 
Dust Allergy 
 Hospitalization 
Any other        _____________ 
Family History 
Any Hereditary/ Familial Disease                      Yes                      No 
If Yes, Details-------- 
Immunization History  
Proper Immunization  given  Yes                    No           ................................................. 
Food habits: 
1. Veg        2. Non-Veg        3. Mixed 
General assessment 
1. Picca  
2. Nail biting 
3. Bowel movements 
General Examination 
1. Pallor    YES  NO 
2. Jaundice   YES  NO 
3. Cynosis   YES  NO 
4. Clubbing   YES  NO 
5. Pedal oedema   YES  NO 
6. Lymph adenopathy  YES  NO 
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Vital signs:- 
1. Pulse rate / mint 
 
2. Heart rate / mint 
 
3. Respiratory Rate / mint 
 
4. Temperature 
 
Anthropometry:- 
Height 
Weight 
 
Clinical assessment 
Affected Parts       
1. Initial lesion/s          : 
2. Number of lesions   : 
3. Colour:      Blackish white (Grey)               Pink                   White 
4. Size of lesion (Measurement in cms.):    
Anatomical location  Length  Breadth Shape  
5. Borders:                     Well-defined                 Diffuse 
6. Erythema:                   Present                   Absent  
7. Sensation:                  Normal                            Parasthesia                    Burning                   
8. Depigmentation of Hair: Present        Absent 
9. Depigmentaion at Muco-cutaneous junctions 
                                          Present        Absent 
10. Itching:                       Present       Absent 
11. Stage of Vitiligo:        Spreading   Relapsing    Static  
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Examination of systems:- 
      Normal  Affected 
Cardio-vascular system:       
Gastro intestinal system:        
Central nervous system:          
Genito- urinary system:          
Endocrine system:  
 
Repiratory system: 
Nilam:- Kurinji  Mullai  Marutham    Neithal   Paalai 
Kaala Iyalbu:-  
 Kaarkalam    Koothirkaalam  Munpanikaalam  
 Pinpanikaalam   Illavenirkaalam   Muthuvenirkaalam 
Yaakai 
 Vatham   Vatha Pitham   Vatha Kabam 
 Pitham    Pitha vatham   Pitha Kabam 
 Kabam    Kaba Vatham   Kaba Pitham 
Gunam  
 Sathuvam   Rasatham   Thamasam 
Pori / Pulangal 
  Normal Affected  Normal Affected Remarks  
    
Mei / unarvu 
Vaai / suvai  
Kan / parvai  
Mooku / natram 
Sevi / olli 
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Kanmendhirium / Kanmavidayam 
       Normal     Affected       Normal            Affected  Remarks 
Kai / dhanam 
Kaal / ghamanam 
Vaai / vaku 
Eruvai / visarkam 
Karuvai / anantham 
Uyir Thathukkal: 
Vatham: 
   Normal  Affected  Remarks 
Pranan  
Abanan 
Viyanan  
Uthanan 
Samanan 
Nagan  
Koorman 
Kirukaran  
Devathathan   
Dhanajeyan      
Pitham  
   Normal Affected  Remarks 
Analam  
Ranjagam    
Saathagam   
Alosagam  
Prasagam 
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Kabam  
   Normal Affected  Remarks 
Avalambagam    
Kilethagam   
Pothagam  
Tharpagam   
Samthigam  
Udalthathukkal: 
   Normal  Affected  Remarks 
Saaram 
Senneer  
Oon  
Kozhuppu 
Enbu 
Moolai 
Sukilam / Suronitham   
Envagai Thervugal 
   Normal  Affected  Remarks 
Naa 
 Niram 
 Thanmai 
 Suvai 
Niram   
Mozhi   
Vizhi  
 Niram 
 Thanmai 
 Parvai 
 
Sparisam  
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Malam 
 Niram  Normal  Affected 
 Nurai  Normal  Affected 
 Elagal  Normal  Affected 
 Erugal  Normal  Affected 
Moothiram 
Neerkuri 
 Niram  Normal Affected 
 Edai  Normal Affected  
 Nurai  Normal Affected 
 Manam Normal Affected 
 Enjal   Normal Affected 
            
 Neikuri              
 Vatham           
Pitham            
Kabam            
Others 
 
Naadi: 
Thani Nadi 
    Vadham       pitham    kabam 
Thontha Nadi 
         Vatha pitham          Pitha vatham       Pitha kabam   Kaba pitham 
Thoda Nadi 
         Vatha kabam          Kaba vatham 
Mukkutra Nadi 
(Signature of principle investigator)     (Signature of Lecturer) 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI–600047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
             A study on “VENPULLI” (VITILIGO) and the drug of choice is 
SENKONRAI KUDINEER (Internal) &  SENKONRAI POOCHU (External).             
 
IV CLINICAL ASSESSMENT FORM 
1. OP / IP No.: ________      2. Patient ID:             3.Name: ________________ 
 
4. Age:   _______ 5.Gender: Male/Female  6.Patient informant: __________ 
 
7. Date: ___________ 8.Reliability   9.Contact No.___________________ 
  
Clinical symptoms 0 After 14 
days 
After 28 
days 
After 
40days 
Site     
Repigmentation     
Number of lesions     
New lesions appearance     
Colour change     
Size of the lesions     
Borders     
Erythema     
Repigmentation of Hair     
Itching     
  
 
(Signature of principle investigator)    (Signature of Lecture) 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600047. 
POST GRADUATE DEPARTMENT OF KUZHANDHAI MARUTHUVAM 
             A study on “VENPULLI” (VITILIGO) and the drug of choice is 
SENKONRAI KUDINEER (Internal) &  SENKONRAI POOCHU (External).             
 
V LAB INVESTIGATION FORM 
Specimen: ____________ 
Date of specimen collected ___/___/______ (dd/mm/yyyy) 
Lab test Normal range Before Treatment After Treatment 
Haemoglobin (gms %) 11.5-15.5gm/dl   
TC cells/cumm 5000-17000cells/µl   
DC- Neutrophil % 40-75%   
Eosinophils 1-6%   
Basophils 0-1%   
Lymphocyte 20-40%   
Monocytes 2-4%   
Total RBC count 4.0-5.2millions/µl   
ESR mm/hr       30min. 
                       1 hour 
1-13mm/hr 
1-20mm/hr 
  
 
 
 
 
106 
 
 
Urine 
Date of specimen collected ___/___/______ (dd/mm/yyyy) 
Lab test Normal Range Before Treatment After Treatment 
Deposits    
Albumin    
 
 
(Signature of principle investigator)     (Signature of Lecturer)  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI – 600 047. 
             A study on “VENPULLI” (VITILIGO) and the drug of choice is 
SENKONRAI KUDINEER (Internal) &  SENKONRAI POOCHU (External).             
 
VI PATIENT INFORMATION SHEET 
Name of the principal Investigator: Dr.--------------------------------  
Name of the institute:   National Institute of Siddha, 
                                         Tambaram Sanatorium, 
                                          Chennai-47. 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
 I,  --------------------------, studying a Post - Graduate Scholar at National Institute 
of Siddha, Tambaram Sanatorium is doing a trial on the study Venpadai (Vitiligo). Vitiligo is a 
common persistent skin disease, occurring throughout the world In this regard; I am in a need to 
ask you a few questions. I will maintain confidentiality of your comments and data obtained. 
There will be no risk of disclosing your identity and no physical, psychological or professional 
risk is involved by taking part in this study. 
 Taking part in this study is voluntary. No compensation will be paid to you for 
taking part in this study. 
            You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, taking part 
in the study may be of benefit to the community, as it may help us to understand the problem of 
defaulters and potential solutions. 
              If you agree to be a participant in this study, you will be included in the study 
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primarily by signing the consent form and then you will be given the internal medicine 
senkonrai pattai kudineer (internal)  5-7yrs…15ml.bid 8-12yrs…30 BD with milk  for 40 
days and senkonrai pattai poochu” (external)  . 
  The information I am collecting in this study will remain confidential. I will ask 
you few questions through a questionnaire. I will not write your name on this form. I will use a 
code instead.  
  The questionnaire will take approximately 20 minutes of your time. 
 If you wish to find out more about this study before taking part, you can ask me 
all the questions you want or contact Dr. ………………………PG Scholar cum principal 
investigator of this study, attached to National Institute of Siddha,Chennai-47. You can also 
contact the Member-secretary of Ethics committee, National Institute Siddha, Chennai 600047, 
and Tel No: 91-44-22380789, for rights and participation in the study.  
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL 
CHENNAI -600 047. 
             A study on “VENPULLI” (VITILIGO) and the drug of choice is 
SENKONRAI KUDINEER (Internal) &  SENKONRAI POOCHU (External).             
 
VII WITHDRAWAL FORM 
1. SERIAL NO OF THE CASE: …………………   
2.OP / IP NO: ......................................    
3. NAME: …………………………  4.AGE: …………       5.GENDER: .................                           
6. DATE OF TRIAL COMMENCEMENT: ………………... 
7. DATE OF WITHDRAWAL FROM TRIAL: …………….. 
8. REASONS FOR WITHDRAWAL: 
Long absence at reporting:              Yes/ No 
Irregular treatment:                          Yes/ No 
Shift of locality:                                    Yes/No 
Increase in severity of symptoms:    Yes/No 
Development of severe adverse drug reactions:  Yes/No 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                              Signature of the HOD 
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  NATIONAL INSTITUTE OF SIDDHA 
ACUTE TOXICITY STUDY OF SENKONDRAI PATTAI KUDINEER 
[WHO guidelines, 1993] 
Principle: 
  Acute toxicity was carried out in Swiss albino mice with a single exposure of 
10 times of the recommended therapeutic dose of test compound the study duration will be 14 
days. 
Animal species  : Swiss albino mice 
Age / Weight / Size  :  6 weeks.  Mice-20-25 gms. 
Gender   :   Both male and female 
Number of Animals   : Mice: 10 
Acclimatization Period : 14 Days 
Clinical dose   : 5.0 gms\day 
S.No Group No of mice 
1 Vehicle control (saline) 10  (5 male, 5 female) 
 
2 
Toxic dose 
10X therapeutic dose 
(144mg) 
10  (5 male, 5 female) 
 
Test Animals  
  Test animals were obtained from the animal laboratory of the King institute, 
Chennai and stocked at National institute of siddha, Chennai. All the animals were kept under 
standard environmental condition (27+ or – 2 degree c).The animals had free access to water 
and standard pellet diet (SaiDurga foods pvt.ltd, Bangalore).The principles of laboratory 
animal care were followed and the  Institutional ethical committee approved the use of 
animals and the study design. (1248/ac/09/CPCSEA/February/ 2012) 
 Route of administration: 
  Oral route was selected, because it is the normal route of clinical 
administration. 
Test substance and vehicle 
  Senkonrai Pattai Chooranam decoction is Brown in colour.  In order to obtain 
and ensure the uniformity in drug distribution the drug is dissolved by normal saline. 
Administration of doses 
  Senkonrai Pattai Chooranam decoction  was suspended in normal saline, with 
uniform mixing and it was administered to the groups in a single oral dose .The control 
groups were received equal volume of the vehicle. The animals were weighed before giving 
the drug. The dose level was calculated according to body weight, and surface area. Since the 
clinical dose was 5.0gms\day it was converted to animal dose (144mg) and then 
administered. The principle of laboratory animal care was followed. 
Observations 
  Observations were made and recorded systematically and continuously 
observed as per the guideline after substance administration. The animals were monitored for 
behavioural parameters like 
1. Awareness 
- Alertness 
- Visual placing 
- Stereotype 
- Passivity 
-  
2. Mood 
-  Grooming 
-  Restlessness 
-  Irritability 
-  Fearfulness 
  
3. Motor activity 
- Spontaneous activity 
- Reactivity 
- Touch response 
- Pain response.  
 Animals were observed for body weight and mortality for 14 days. If animals 
died during the period of study, the animals were sacrificed.  At the end of the 14th day all 
animals were sacrificed and necropsy was done. 
Body Weight 
  Individual weight of animals was determined before the test substance was 
administered and daily for 14 days. Weight changes were calculated and recorded. At the end 
of the test, surving animals were weighed and sacrificed. 
Results:   
Senkonrai Pattai Chooranam decoction the dose 144mg/animal did not exhibit 
any mortality in mice. 
  No behavior changes were noted for the first 4 hours and for the next 24 hours 
and throughout the study period of 14 days. No weight reduction was noted before and after 
the acute study duration. Reflexes were found to be normal before and after the study. All 
other observations were found to be normal before and after the study. In Necropsy, the 
organs of the animal such as, Liver, Heart, Lungs, Pancreas, Spleen, Stomach, Intestine, 
Kidney, Urinary bladder, Uterus all appeared normal. 
 
 
 
 
 
